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Clinical Procedures 
Current Techniques in Carotid Artery Stenting: A Synopsis 
Paul Lau, Meds 2011 
Reviewed by Dr. Stephen P. Lownie 
Introduction 
Cardiova cular di sea e and tro ke are the leading 
cau e of death in Canada. Approx imately 
15,000 Canadians will die of troke every year 
and 300,000 people will be li ving with its 
effec ts. 1 In the United States of Ame1ica, 30% of 
all stroke related death were associated with 
carotid artery le ions,2 a tati tic likely imilar in 
Canada. 
The commone t carotid artery disease is 
teno i , where there i narrowing of the carotid 
artery lumen. Becau e the carotid arteries are the 
principal blood upply to the brain , decrease of 
fl ow as a result of stenos is can cause transient 
i chemic attacks or in the ca e of complete 
occlusion, cerebrova cular accidents? The 
majority of carotid arte ry stenos is case are a 
re ult of atherosclerotic pl aque accumulation in 
the wall of the arteri e . Therefore, a secondary 
ri k factor in carotid atherosc lerotic steno i 
is the di slodging of emboli to the 
cerebrovasculature. 3 Indeed, the rupture or 
di lodgement of plaques cau ing down tream 
emboli account for the majority of carotid artery 
stroke . 
Pati ent with carotid stenos is can be 
asymptomatic or present with a tran ient 
i chemic attack or stro ke.2·3 Di agnos is is made 
u ing several technique. . Upon phy ical 
examin ation, carotid au cultation may reveal 
a carotid bruit. omputed tomography 
angiography, magneti c resonance angiograph y or 
carotid duplex ultra onograph y are various 
imag ing modalities u ed to di agnose suspected 
carotid steno is.4 Furthermore, these images 
permit the surgeon or interventionali st to 
calcul ate the degree of teno is, an important 
con iderati on in tenns of deciding between 
variou treatments. 
Several treatments have been approved 
for improving outco mes of pati ents with carotid 
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artery stenosis. Currently, endarterectomy or 
urgical removal of the narrowed carotid 
egment is the accepted and most widely used 
treatment for carotid teno i 5 ; however, carotid 
artery tenting ha ri sen a a non-invasive 
alternative for orne patient with the aim of 
restoring the carotid lumen.4 This article will 
ex plore the procedural aspect of carotid stenting 
and pre ent the indication and contraindication 
fo r thi intervention. 
Carotid Stenting 
Procedure 
The non-inva ive nature of carotid tenting 
permits the pati ent to be awake during the 
procedure. Thi allow the physician to monitor 
the patient 's neuro logical tatus;2 an important 
con ideration due to the po ibility of embolism 
to the cerebral ve e l . The procedure i 
performed in an angi graphy suite under the 
guidance of flu oro copy. Contrast agent are 
constantly admini tered to direct catheters and 
confirm po itioning of balloon and tent . 
A needle is inserted into the common 
femoral artery under local anaesthesia. A radio-
opaque guidewire i then threaded through the 
needle and advanced into the abdominal aorta.6 
The needle is ub. equ ntl y removed and a heath 
i placed over the guidewire and advanced to the 
aorta. At thi po int, the guidewire is al o 
removed and the sheath act a a catheter by 
which other catheter and wire can be placed 
and guided towards the tenos is?·6 
Using catheter , a preliminary carotid 
angiogram i conducted to demonstrate the 
degree of teno is (expres ed a a percentage) 
and a e s for artery ize downstream of the 
le ion. This allow the phy ician to choose the 
appropriate Embolic Protection Device (EPD) 
and tent based on degree of steno is and ize f 
the artery re pectively. 2 A cerebral angiogram i 
also perfonned to rule out any contraindication 
to carotid stenting. Appropriately, heparin is 
administered to prevent clotting and its effect is 
measured using the Activated Clotting Time 
(ACT). The ACT in thi s procedure should 
exceed 250 seconds. 
An EPD i a specially des igned umbrella 
haped device that is used to capture debri s and 
emboli as a result of either Percutaneous 
Transluminal Angioplasty (PTA) or the release 
of a stent compressing the artherosclerotic 
plaque.7 Before the stent is placed, an EPD is 
deployed upstream with re pect to the site of 
stenosis. The use of an EPD has shown to reduce 
the ri k of ischemic attack 30 days post 
procedure to 2.2% from 5.3%? This has 
prompted the routine use of an EPD by many 
interventionalists. If the degree of con triction is 
too evere to safely allow an EPD through , PTA 
with a small balloon may be appropriate to allow 
for safe pa sage of the EPD. 
At this point, a sheath covered stent is 
introduced and directed towards the site of the 
lesion . The sheath is peeled and removed and the 
stent is positioned in the stenotic portion of the 
artery.6 The stent is self expandable and will 
effectively reduce the degree of stenosis. 
Following stent deployment, an angiogram is 
obtained to confirm the increase in diameter of 
the artery. 
In severe cases of stenosis, the stent itself 
may only reduce the occlusion mildly? To 
combat the high degree of post procedure 
stenosis, a balloon catheter may be placed within 
the boundaries of the stent and expanded to 
allow for greater augmentation of the vessel 
diameter. Similarly, it i essential to confirm 
with an angiogram the degree of post procedure 
stenosis. Importantly, the placement of the 
balloon should not extend further then the 
margins of the stent. Damage resulting from 
inflation of exaggerated balloons may cau e 
damage to vessel walls and increase the ri sk of 
restenosis. Angiogram confirmation of arterial 
lumen expansion is followed by catheter 
dependent removal of the EPD.2·6 
Results from a recent study proposed that 
because pre- and post-stent deployment balloon 
angioplasty may be the major cause of dislodged 
emboli in carotid stenting procedures, that 
removal of the e step in carotid tenting would 
eliminate the need for EPDs.8 This study 
demonstrated that the u e of elf expanding 
stents alone provided moderate allev iation of 
teno i with increasing lumen diameter for up to 
one year. In conjunction, none of the patient in 
the study had a troke as a direct result of the 
procedure. The implications of this tudy are 
twofold . Firstly, PTA may be the majo r cau e of 
emboli related complications in carotid tenting 
and secondly, if PTA is not u ed within the 
procedure, EPDs may not be necessary. 
Effectively, the e modifications to the carotid 
stenting technique may provide future 
interventionalists with a afer, quicker, more cost 
efficient procedure. 
Pre-procedure Considerations 
Carotid tenting is only advised over 
endarterectomy in a subset of patients. Currently, 
within the context of a randomized control trial, 
any symptomatic patient (transient ischemic 
attacks or stroke) with greater than 60% carotid 
artery stenosis or asymptomatic patients with 
greater than 80% stenosis are eligible for carotid 
stenting? Additionally, individual deemed to be 
at a high ri sk for surgery or who have had a 
previous endarterectomy with recurrent stenosis 
are also eligible for stenting. Some exclusion 
criteria include individuals with torturous aortic 
arches , unfavourable anatomy, inaccess ible 
lesions and patients with contraindications to 
anticoagulation therapy. 
If approved for carotid artery stenting, 
patients should undergo a full neurological 
examination as well as a neurological angiogram 
24 hours pre-procedure. Antiplatelet therapy 
should be given four day prior to the 
intervention; however, patients who are over 80 
years of age may require longer treatment 
periods. Acetylsalicylic acid and clopidogrel are 
administered once daily to the patient. 6 
Post-Procedure Considerations 
Following the intervention , the patient ' blood 
pressure should be kept under 160mm Hg and 
antiplatelet therapy continued for 6 weeks. 
Following these 6 weeks, the patient should be 
advised to continue acetyl salicylic ac id 
treatment for the duration of their life. 
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Conclusion 
Although endarterectomy ha proven hi ghly 
ucce sful in the treatment of carotid artery 
steno i , carotid artery tenting has emerged a 
an alternative. On the pati ent level, carotid 
tenting may prove to be a safer procedure 
for specific indi vidual . However, stenting 
of the carotid artery is a technically 
challenging intervention with numerous potenti al 
complication that make it unfavo urable a 
a standard therapy when compared to 
endarterectomy.4 Recent tudie have hown the 
non-infe rior nature of carotid artery tenting 
compared to carotid endan erectomy in a tri al 
u ing asymptomatic pati ent with greater than 
80% teno is or ymptomatic pati ents with 
greater than 50% teno i .9 However, increa ed 
ri k of post procedu re complications of tenting 
have been documented in a tri al consi ting of 
only ym~tomatic patient with greater than 60 
steno i .1 These tudies demon trate that in 
pecific pati ent populati ons stenting may be 
preferred but upport fo r carotid artery stenting 
a a routine treatment for carotid stenos is is 
lacking. 
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Diagnostic Review 
Innovations in Cardiac Computed Tomography: Cone Beam CTN olume CT and 
Dual Source CT 
Jaron Chong, Medicine 2010 and Jason Essue, Medicine 2011 
Reviewed by Dr. Ali Islam 
Two recent innovatio ns in cardi ac Computed Tomography (CT) o f Cone Beam CT or Volume CT (VCT) and more 
recentl y, Dual-Source CT (DSCT) o ffe r phys ic ians c linica ll y viable a lternati ve to in vas ive coronary angiography for 
the imaging o f coronary artery stenoses. Performing the procedure termed CT angiography or Multi -Detector CT 
angiography, both technologies provide the neces ary pati al and temporal re o lution, in addition to a vari ety of o ther 
ad vantage to image the cardiac patient. Both report improvements over conventional CT with reduced acquisition time, 
greater image quality , and with DSCT an ability to perform cardiac imag ing on tachycardic patient a well as reduce 
radiation dose, all without compromising image quality. While onl y being two example of new technologie in cardi ac 
imaging, VCT and DSCT represent the current and next steps, in what pro mi ses to be many exciting developments to 
come . 
Introduction 
The field of Computed Tomography (CT) has 
realized many significant developments over the 
past four decades that have dramatically 
improved the clinical applicability of this 
technology. 1 CT became widely available in the 
1970s with the introduction of ingle-detector 
CT canners that captured one slice per rotation . 
In 1992, the first Multi-Detector CT (MDCT) 
scanner was produced (CT-Twin, Elscint) 
capturing two slices per rotation. 2 Since then , the 
field has advanced to the point where modem 
MDCT scanners are routinely able to capture up 
to 64 slices per rotation. 3 
The past decade has seen multiple 
generations of CT scanners emerge, and when 
64-slice scanners first arrived, the ensitivity and 
specificity of detecting coronary artery stenosis 
via CT angiography began to approach that of 
invasive angiography.4 In year pa t, what some 
in the press have dubbed the 'slice wars' 
between the four major vendors of GE, Siemens, 
Toshiba, and Phillip in the push for greater 
spatial and temporal resolution has evolved into 
a more complex marketplace with different 
vendors pursuing different strategies.5 Toshiba 
has decided to pursue greater slice count to an 
industry record of 320 slices and coverage area 
up to 12cm. 6•7 Phillips has taken efforts to 
increase the gantry rotation speed (i.e. the speed 
at which the X-ray sen ors rotate around the 
patient) which in conjunction with reconstruction 
algorithms provides a temporal resolution of 
270ms.8 However, for the purposes of this 
article, we will be reviewing in greater detail 
GE's Volume CT (VCT) and Siemens' Dual-
Source CT (DSCT) systems. 
-~~ 
Figure 1: 30 Vo lume Rendering of the Heart. 3 
Cardiac CT Imaging 
With re pect to cardiac imaging, many efforts 
utilizing CT have focu sed on the imaging of 
coronary artery steno es, a technique tem1ed CT 
angiography or MDCT angiography (Figure 1). 
In comparison with the gold tandard of invasive 
conventional coronary angiography, non-
invasive CT has the advantage of avoiding ri ks 
of arterial vascular complications such as arterial 
punctures, vessel damage, and dislodged aortic 
plaques causmg myocardial infarct or stroke. 
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Estimate place the total risk of an adverse event 
between 1.7-2.0% for all causes.9- 11 In contrast, 
the major ri sks of CT angiography are a reaction 
to intravenous contrast and the radiation dose 
potentially cau ing cancer, both of which are 
equally present in traditional inva ive 
angiography. The risk of a severe or fatal 
anaphylactic reaction to contrast is estimated at 
0.04% and the lifetime ri sk of dying from cancer 
due a CT angiography can is estimated to be 
le s than 0.1 %.9 With regards to the radiation 
dose, significant advance have been made to 
decrease the radiation absorbed while 
maintaining image quality and is the focus of 
much active re earch. 
Cardiac imaging poses the very unique 
challenge of imaging a moving target, requiring 
any clinically effective scanner to complete an 
image acquisition during an akinetic end- y tolic 
or dia tolic period. 12·13 A a natural consequence 
of thi , the faster a scanner can complete a 
rotation to avoid parts of the cardiac cycle with 
motion, the clearer the image will be, generall y 
speaking. This quick scanning speed also prove 
advantageous during tachycardia without the 
need to use drugs like beta-blockers for heart rate 
control. 
Cone Beam CT/Volume CT 
Conventional MDCT canners collect 
projection from a fan beam of x-ray .14• In 
compari on, Cone Beam CT or Volume CT 
(VCT), expand the x- ray beam from a fan to a 
pyramid or cone (Figure 2). 3' 14 A computer 
algorithm then proces es the 20 cone-beam 
projections into a 3D image of a patients' 
)( , ItA_ Y S OU RCC 
X ·MAY COH£ UEAM 
O IIJ Cl ROTATC5 IN 
K· RAY BE t.M TO Tt. K E 
IMAGES DATA FAOM 
All .I<_HG LES 
Figure 2: Cone-Bea m CT concepl. 14 
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anatomy. With the advent of scanners a?le to 
capture up to 64-slices per rotation, this has 
created the platform necessary for Volume CT to 
emerge.3 
One such scanner is the LightSpeed VCT 
model introduced by General Electric (GE) in 
2004. GE's LightSpeed VCT canner features a 
64-slice detector and rotation speed of 370 
milli second with slice widths of 0.625-
millimeters, enabling the system to generate 64 
sub-millimeter images totaling 40 millimeters of 
. . h . 1 . 14, ts GE anatomic coverage wtt a mg e rotatiOn. 
attributes orne of the image acquisition 
improvement to the development of a new 
detector technology named V-Res, which is able 
to acquire 64 channels of data while spinning at 
le than 0.4 second per rotation .3 
The combination of high volume and 
high re olution demon trated by the LightSpeed 
VCT scanner translates into three major tangible 
clinical benefit : 
Dramatically reduced acquisition time: Scanning 
time i half that needed for conventional MDCT 
scanners. Static organ can be imaged in one 
econd, the lung in two econds, the heart and 
coronary arterie in fewer than five econds, and 
a whole body scan in les than 10 seconds.3•15 
The quicker imaging process more 
comfortable for patients because it requires 
horter breath-holds, can be especially u eful for 
trauma patients when time i of the es ence, and 
may help to allevi ate lengthy queue for 
diagno tic imaging given that a hi gher volume of 
patient can be imaged on a given day. 3 
Improved image quality: The characteri tic thin 
s licing capacity of the Volume CT allows for the 
generation of hi gh resolution image , which 
translates to better diagnostic accuracy.16•17 In 
addition , multi-planar reformatting of images in 
any plane, including curved planes, i al o 
po ible. This improves the depiction of 
pathologic features paLticularly in cardiac 
imaging because such tructure do not lie in the 
tandard planes (x , y, z), which also improve 
diagnostic accuracy. 18•19 
New diagnostic possibilities: Volume CT offers 
the po sibility to acquire a complete angiooram 
within five heartbeat (at 60 beat fmin 
approx imately 5 seconds) making the procedur~ 
less u ceptible to irregular heartbeats, helping 
phy ician rule out, or in , the three main causes 
of life-threatening ER chest pain (i.e. aortic 
dissection , pulmonary embolism, and coronary 
artery di ease) in one can, and en ure a more 
thorough troke work-up because the entire 
Circle of Willis can be dynamically acquired 
with high resolution. 3 
More recently in 2007, GE introduced the 
LightSpeed VCT XT scanner (an improved 
ver ion of their LightSpeed VCT canner) that 
operates on a new scanning platform called 
'SnapShot Pulse', which claims to reduce 
radiation dosage by a much a 70-83% when 
compared to conventional helical techniques 
without compromi ing image quality by pul ing 
the x-ray beam during akinetic portions of the 
cardiac cycle as orposed to continuously 
engaging the beam?0-2 
Dual-Source CT (DSCT) 
Dual-Source CT, a more recent development, 
innovates upon modem CT system by utilizing 
multiple X-ray source and detectors to reduce 
the length of time required to perform one 
canner pas . A of thi s writing, the only 
commercially DSCT sy tem available, known a 
the SOMATOM Definition, is manufactured by 
Siemens Medical Solution . Utilizing two X-ray 
tube sources and two corresponding detectors 
offset by 90·, the SOMATOM system yields 
significant gains in temporal resolution making it 
ideal for cardiac application (Figure 3)?3 
In a typical single- ource CT canner, the 
length of time required to perform a scan i 
Figure 3: Configuration of Dual-Source CT scanner with 
two X-ray tube sources and two corresponding detectors 
90. 24 offset by . 
limited by what is known a the 'gantry rotation 
time' which can range from 0.33s to 1.0 . Thi i 
the amount of time it phy ically takes to rotate 
the fan-shaped X -ray source and detector 180. 
through the field of view gathering the necessary 
images to re-con truct a slice or array of slices. 
By utili zing the second-source X-ray tube and 
detector array, the time taken i halved to 165m 
while maintaining equivalent spatial resolution ? 5 
Steady Imaging Up To 100 BPM: The ability to 
image at this enhanced speed has numerous 
implications for the cardiac imaging challenges 
mentioned earlier. DSCT allows for teady 
imaging of the heart irre pective of heart rate up 
to 100 beats/min whereas a ingle-source CT can 
only guarantee temporal re olution at 66 
beats/min or lower (Figure 4)?6 Thu , with 
single-source CT, stringent protocols are 
required duting Coronary CT Angiography 
(CCTA) to lower a patient ' s heart rate to less 
than 65 beats/min using beta-blocker . Such 
compensations are optional with DSCT.27•28 
Increased Pitch/Reduced Radiation Dose at 
High Heart Rates: Another advantage of DSCT 
is the ability to increase pitch (i.e. the speed at 
which the patient is advanced through the 
scanner) for any given heart rate thereby 
reducing the duration of time the patient is 
exposed to radiation, and hence, overall radiation 
dose. A study conducted by McCollough et al. 
examined the dose performance of the 
SOMATOM in comparison to traditional multi-
detector CT. 29 The study noticed a dec rea e m 
radiation exposure when radiation do e 
22( .---~--~--....--------., 
~l 
4 (~-~~~~~-~~~~--~ 
~o t.o ;c :3· ~r-
Heart rate in bpm 
Figure 4: Comparison of ingle-source versu dual- ource 
CT. Note the preservation of temporal resolution despite 
increasing heart rate. 24 
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optimization methods were used for patients with 
high heart rates close to a factor of 2 (At >90 
beats/min: 26.6mGy DSCT vs. 43.7mGy 
MDCT). However, this advantage is lost and 
almost completely reversed when imaging at 
very low heart rates (At <55 beats/min : 6 1.2mGy 
DSCT v . 28.7mGy MDCT).29·30 
Consistent Image Quality: All of these 
advantage would not be particularly useful if 
di agnostic quali ty were compro mi sed bu t DSCT 
maintain high standards in spite of high heart 
rates . Matt et al. managed to demonstrate no 
significant correlation between between mean 
heart rate and image quali ty in a population of 80 
patient that underwent DSCT, with heart rates 
ranging from 35 to 99 beat /mi n.31 In contras t, 
o ther studie with 64- lice MDCT have hown a 
decrea e in image quality with inc reas ing heart 
rate.32,33 
Conclusion 
Both Cone-Beam CT I Volume CT and Du al-
Source CT represent two example of recent 
developments in cardiac imaging. While vendor 
have an interest to push the edge of techno logy 
to even greater height , re earchers, clinic ians, 
and policy makers have an equally important 
re ponsibili ty to evalu ate the e new techno logies 
with an eye toward efficacy, clinical benefi t, and 
proper indications for u age. Numerous 
developments in CT scanners are cutTently 
undergo ing clinical evaluation,18 and research is 
being conducted into further strategies for both 
reducing radiation do age while improving 
image quali ty. Several vendors are already 
looking at dual-energy CT that has the potenti al 
to improve characteri zation o f varying tissue 
densiti es and minimi ze metal image artifacts? 4 .35 
It may be many years before we see wide-spread 
adoption o f the e techno logies here in Canada, 
but there can be no doubt a to the important 
implications of work like thi . Two sources or 
one, 320-or 64-s lices, cardiac imaging is only 
just getting started . 
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Ethics 
The Aprotinin Story: Lessons in Drug Regulation and Safety 
Adam Katchky, Medicine 2010 and Christina Morgan, Medicine 2011 
Reviewed by Drs. Lois Champion and Mark Speechley 
Issues of drug regulati on and safety are a fami li ar concern within the pharmaceutical industry and often do not emerge 
until several year after a drug ha been on the market. The antifibrinolyti c drug aprotinin (Trasylo l) was developed 
by Bayer Pharmaceutica l and approved to prevent excessive bleeding in patients undergoing coronary artery bypass 
grafting surgery. After evera l year o f widespread use o f the drug in cardiac procedures, two ob ervational studies 
demon trated a ri k of aprotinin for erious complications such a renal failure and myocardial infarction. These 
observations led to a prol onged review of the drug 's safety label by the Food and Drug Adrniru tration and to the 
revelation that Bayer had withhe ld the result of a private ly commis ioned observational study which demonstrated 
these reported complicati ons. This essay highli ghts the ethical issues rai sed by the aprotinin aga and di cu es the 
importance of transparency, honesty , and clinica l equipoise in drug regul ation and safety. 
Timeline 
On December 30, 1993, the Food and Drug 
Administration (FDA) announced it approval of 
the antifibrino lytic agent, aprotinin , developed 
by Bayer Pharmaceuticals and marketed under 
the trade name Trasylol for use in cardiac 
urgery. 1 Antifibrinolytics have long been a 
mainstay of treatment to prevent excessive 
bleeding, a frequent cause of morbidity and 
mortality in patients undergoing on-pump 
coronary artery bypass grafting (CABG) and 
other cardiac procedures. Traditional 
antifibrinolytic agents, including an1inocaproic 
ac id (ACA) and tranexamic acid (TXA), often 
take the form of lysine analogues that prevent 
bleeding by interfering with the activation of 
plasminogen to plasmin, a molecule re ponsible 
for the degradation of fibrin clot . Aprotinin is 
unique in that it promotes c lotting by inhibition 
of erine proteases, including pia min, thereby 
preventing the degradation of the plasma 
protein compri s ing fibrin c lots. 
The initial FDA approval was ba ed 
primarily on two randomized, placebo-controlled 
clinical trials. One study reported that 77% of 
patients who rece ived no bleeding prevention 
therapy required at lea t one transfusion dllling 
or after the operative procedure ; among patients 
who had received aproti nin , on ly 42% required 
the administration of blood products? The 
second study showed similar result .3 However, 
the author also noted the possibility of allergic 
reaction after chronic usage, as well as incidents 
of kidney toxicity. Although these adverse 
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effects were sufficiently rare and manageable to 
permit drug approval, aprotmm was 
recommended for u e primarily m high risk 
patients. 
In the year following its approval, 
aprotinin gained acceptance into the practice of 
cardiac surgery. Over 70 tudie were conducted 
to e tabli sh and confirm the efficacy of aprotinin 
by measuring the blood product transfu ion 
requirements of patients undergoing cardiac 
bypa s procedures, with or without aprotinin. A 
placebo-controlled, double-blind study 
conducted by Bidstrup et al. , for example, 
demonstrated a significant reduction in blood 
unit required in a high do e aprotinin group 
following cardiopulmonary bypas .4 While 
numerou studie uch a this confim1ed it 
efficacy, little hint of the ri sk of aprotinin was 
found beyond the initially reported side effect . 
Thi was due in large patt to the fact that the 
primary endpoint of the majority of the e 
studies, including that conducted by Bidstrup et 
al. , were transfu ion requirements , and the 
tudies were frequently not de igned or powered 
to detect mortality benefit or specific adverse 
outcomes. While donor blood requirements may 
be used a an indicator of blood loss the e 
studies failed to address ' patient im~ortant 
outcomes' such as morbidity or mortality. 
By 1998, the FDA had expanded the 
indications for aprotinin use to all CABG 
patient 4 and its use burgeoned as it became the 
mainstay of bleeding prevention therapy in 
cardiac urgery. Thi was aided largely by it 
newly expanded recommendation, a well as a 
lack of other drugs indicated for thi s purpose, as 
the ly ine analogue antifibrinolytics such as 
TXA were initially developed to prevent 
bleeding in other procedures and condition .5 For 
everal years, the ri k of anaphylactic reaction 
with repeated administration remained one of the 
only ri sks identified with aprotinin use. 
The fir t study to raise concerns 
regarding the safety of aprotinin was conducted 
by Karkouti et al at the University of Toronto, 
and wa published online ahead of print in 
Transfusion on January 20, 2006.6 This 
observational study employed a method known 
as propen ity scoring to compare risk-variable 
patients who received aprotinin or tranexamic 
acid. Propensity scoring i a statistical technique 
used to control for selection bias in observational 
studies where treatment allocation is not random, 
and involves detennining the probability, or 
propensity score, of receiving a particular 
treatment based on a number of background 
variables , or covariates, which may plausibly 
influence treatment as ignment. Whjle aprotinin 
and TXA were found to be quite similar in 
effectivene s with respect to transfusion 
requirements, the former was associated with a 
statistically significant increase in renal 
dysfunction within the first postoperative week, 
sometime requiring dialysis.6 On January 26, 
2006, a similar study conducted by Mangano et 
al. was published in the New England Journal of 
Medicine.7 This multi-centre observational 
study examined nearly 4500 patients who were 
administered either aprotinin , aminocaproic acid, 
tranexamic acid , or no treatment. Through 
propensity scoring and multivariate analysis, 
they found that aprotinin was associated with a 
significantly increased risk of renal failure , 
myocardial infarction, heart failure, stroke and 
encephalopathy, while ACA and TXA were not 
associated with these adverse effects.7 A 
subsequent follow-up tudy by Mangano et al. 
also demonstrated increa ed risk of long-term 
mortality associated with aprotinin.8 
These two studies prompted the FDA to 
initiate a year-long review of the safety of 
aprotinin, and to convene a meeting of it 
Cardiovascular and Renal Drug Advisory 
Commission on September 21 , 2006. The FDA 
chose neither to amend the label on aprotinin nor 
to issue any additional safety warnings 
urrounding potential adver e effect . The 
primary outcome of the meeting was a reiteration 
of the initial recommendation that aprotinin be 
used only in high ri sk patients. In defending 
their deci sion, FDA committee representatives 
cited issues of transparency related to an 
unwillingness to release data on the part of 
Mangano et al. 9 Mangano responded in a letter 
to NEJM, indicating that although their data 
release was initially offered with re trictions 
related to patient confidentiality and independent 
analysis, it was eventually offered without 
re triction prior to the committee meeting and 
following a lengthy delay in acknowledgment of 
their data or requests by the FDA.10 He further 
indicated that, despite repeated requests, the 
FDA infonned him that a review of his data was 
unnecessary at that point. Six days following 
adjournment of the meetings, however, Bayer 
relea ed the troubling results of an observational 
study it had commissioned. These findings 
demonstrated that the use of aprotinin led to an 
increase in kidney damage, congestive heart 
failure, stroke, and mortality, and quickly 
triggered erious safety warning with re pect to 
the drug. 11 
Following the revelations regarding the 
safety of aprotinin, many sought to determine 
what had gone wrong. What they found , 
however, was even more di turbing than what 
had already transpired and raised seriou issues 
with respect to manufacturer transparency and 
deception regarding adverse drug effects. Bayer 
hired a private contract research team to conduct 
their observational study on the postoperative 
complications of aprotinin use, and their findings 
were similar to those of Mangano et al. 12 Further 
inve tigation revealed that Bayer official were 
given the preliminary re ults before the FDA 
review meetings, yet neither the manufacturer 
nor the private contract team had shared thi 
information with the regulatory body. They 
explained that an internal mistake resulted in the 
delayed release of thi information .13 However, 
investigation into the body of evidence which 
initially supported the efficacy of aprotinin 
revealed that Bayer repeatedly funded numerous 
small trial which showed the drug to be 
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effective, but were underpowered to show any 
rare but serious adverse effects. Meta-analysis 
later showed that on average these trials 
referenced only 20% of the preceding reports; 
only 15% referenced the largest trial , which is 
considered to be central to the evidence 
urrounding aprotinin. 14 
Ethical Analysis 
The aprotinin ca e serve to highlight numerous 
ethical i sues with drug regulation and safety a 
they pertain to the pharmaceutical indu. try. 
While public intere t and patient safety should be 
central prioritie in all healthcare activities, these 
can be overlooked or ignored by pharmaceutical 
companies in favor of drug marketing. However, 
in this instance, ethical i ues are raised not only 
by Bayer's actions, but also by those of the FDA 
and the researchers who ounded the alarm. 
FDA: According to Mangano, the FDA did not 
respond to his repeated requests for data review 
prior to upholding the aprotinin label, citing it 
was unnecessary. In hi response to the FDA 's 
decision, Mangano stated, "The FDA and its 
Advisory Committee should take a conservative, 
protective stance when independent evidence 
regarding drug safety presents itself. Instead, 
they appear to be protecting the drug rather than 
the patient." 11 
While ethical discuss ion centered on drug 
regulation most often foc uses on the behavior of 
pharmaceutical companies, the aforementioned 
interactions between Mangano and the FDA call 
into question the prioritie of the regulating body 
as well. While the FDA did request the data 
from the Mangano study upon convening it 
Advisory Com miss ion, it appear as if the FDA 
did not make every effort to obtain the data via 
di scus ion with Mangano before judging the 
safety of the drug. This raises questions a to the 
efforts of the FDA and the nature of the 
influence of pharmaceutical companies on their 
regulatory body. 
Mangano: While the researcher did offer the 
original . tudy data to the FDA, there appeared to 
be initial resistance to do so in that data release 
was contingent upon several restnctJOns 
including pati ent confidenti ality and independent 
data analysis. This rai e the issue of 
transparency in research , and the situation in 
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which researchers should be encouraged or 
obligated to share their data and their anal~tical 
methods. Methodological transparency IS . of 
particular importance in observational stud1es 
where treatment allocation is not randomly 
assigned and certain analytical s trat~gies are 
required in order to minimize known b1ases and 
approach a true evaluation of effect. Often these 
are the only means by which critical drug safety 
issues can be evaluated. Thus transparency 
becomes a central value in research ethics. 
However, the concept of transparency itself 
rai e further ethical i sues, as the obligation the 
release indi vidual-level data may conflict with 
the value of privacy and anonymity. 
Bayer: Bayer face the erious charge of 
withholding information garnered from a 
privately conducted tudy at the time of the FDA 
commi sion. This goes beyond the concept of 
tran parency and encroaches on honesty, which 
mu t undoubtedly be a central value in all 
research acti vities. It ha become clear that 
Bayer became aware of at least the preliminary 
resu It of the study, yet they did not di sclose thi s 
information to the FDA Advi ory Comrni ion in 
a timely manner. Drug afety analy es are often 
an is ue because we rely on pharmaceutical 
companie to fund the tudie necessary to assess 
safety; however, when they have a vested 
intere t in the lucrative succe of their product, 
it i difficult to expect them to fund or disclo e 
the re ult of tudies that might disc redit their 
product or jeopardize it succe . 
Finally, and most ubtly Bayer' 
inve Li gation of the effectiveness of aprotmm 
remains in tark contrast with the principle of 
clinical equipoise. Thi principle tates that 
randomized control trials can only be conducted 
ethically when true di agreement exi t as to the 
effectiveness of one treatment compared to 
another. In placebo-controlled studie , it is only 
ethical to admini ster no treatment (or a placebo) 
whe~ no proven treatment exi ts. Bayer 
contmued to fund placebo-controlled RCTs 
de pi~e. the previou literature supporting 
aprotmm as an effective treatment for decrea ino 
tran fu sion requirements. In hind ight, thi~ 
appear to have been done in order to build the 
body of evidence supporting thi s therapy, and to 
continue to show effectiveness without being 
able to identify adverse effect a ociated with 
it admini tration. These tudie , while 
ufficiently powered to detect ignificance of 
efficacy, were for the mo t part too mall to have 
a high likelihood of howing serious and rare 
side effects. These actions further contributed to 
the skewed view of aprotinin held by both the 
public and the medical community, and to its 
longtime u e de pite its dangers. 
Conclusion 
The protracted length of time between the 
approval of aprotinin for the prevention of 
exce ive bleeding during coronary artery bypa 
grafting and the revelation of drug afety 
concern indicates a need to refine the process of 
drug afety revtew. The ethical tssues 
highlighted by the action of Bayer 
Pharmaceutical , the Food and Drug 
Admini tration , and the drug researchers indicate 
that drug safety is not influenced olely by the 
philo ophies of pharmaceutical corporation , but 
instead it involves complex political and 
procedural interactions between the 
pharmaceutical companie , the regulating body, 
and drug inve tigators. We have indicated a 
fundamental requirement for transparency as it 
pertain to all studies asse sing dntg afety, 
particularly on the part of the pharmaceutical 
compante . As observational tudies are often 
the only means by which we can assess long-
term drug safety, it i al o important that they be 
tran parent and sufficiently powered to detect 
long term morbidity and mortality. While the 
aprotinin aga repre ent a very recent example, 
other drugs including flecainide acetate 
(Tambocor) and ro iglitazone (Avandia) have 
rai ed imilar i sue in the past decade. Major 
change are required to refine the evaluation and 
monitoring of pharmaceutical products following 
regulatory approval and widespread use. These 
acti vi tie are critical to treatment effecti venes 
and patient safety. 
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Heart Health or Hype? Exploring the effect of diet trends on cardiovascular disease 
Jonathan Klein, Medicine 2010 and Laura Hinz, Medicine 2011 
Reviewed by Dr. Lynn Bergin 
Certain foods have been touted a providing pecial benefits in preventing cardiova cular di. ease. We reviewed the 
l i terature upport ing cardioprotecti ve effec ts from cranberries, chocolate, dairy foods, and omega-3 fatty acid · T o 
varying degrees, all four of the e ca tegorie of food provide demonstrated benefi t for heart health . For each food 
investi gated, we provided insight into how they ca n be incorporated into a healthy li fe ty le along with orne caveats 
again t their overuse. A balanced, nutri tious diet including orne of the e food , combined with an acti ve life ty le, can 
provide proven benefi ts for cardiova cular hea lth . 
Introduction 
The importance of eating a balanced diet and 
engaging in regul ar exerci e for the maintenance 
of good health is generally accepted as common 
ense and is upported by rigo rous sc ientifi c 
in vestigati on. 1 Obe ity and inactt vtty rate 
continue to ri e teadily, however, bringing with 
them a ho t of di sorder such a diabetes mellitu 
and cardiova cular di ease (CVD). In the face of 
increa ed CVD incidence, many food have been 
touted as being especiall y good for the heart. In 
thi article, we in ve ti gate the biochemistry and 
evidence fo r the cardioprotective effect of 
cranberries, chocolate, dairy foods, and omega-3 
fatty acid , which have all received attention for 
their potentially heart healthy properti es. 
Cranberries 
Evidence and Biochemistry: Cranberri es have 
been pro moted for putati ve wide-ranging health 
benefits, o much o that the journal Criti cal 
Reviews in Food Science and Nutrition devoted 
an entire 2002 issue to ex to lling the fruit 's 
virtue . From preventing urinary tract infections2 
to protecting against gastri c ulcer 3 to reducing 
the ri sk of cardi ac events, 4 cranberri es have been 
credited fo r providing ignificant health benefit 
beyond those of other fruit . 
Several large tudies, including the 
lNTERHEART tudy,5 have shown significant 
health benefits from diet high in fruits and 
vegetables, such as the Mediterranean Oiet.6 
Though many mechani ms for the e re ults have 
been proposed, much attention has focu ed on a 
class of compounds called flavonoid , which are 
present in high concentrations in cranberri es and 
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other fruit .7 Flavonoid are a group of 
molecules with a common diphenylpropane (C6-
C3-C6) moiety, which contain two aromatic 
ring linked by a ix-member ring. There are ix 
different categories of flavonoids characterized 
by variation in the central ring. 8 Cranberries 
contain many different flavonoid classes 
including flavonol , fl avan-3-ols, and 
anthocyanin .9 
Flavonoids have been identified as 
cardioprotecti ve compound due to their 
antiox idant effect . 11 Substantial ev idence has 
demon trated that oxidation of low den ity 
lipoprotein (LDL, the o-called "bad 
chole tero l") conttibute to atherosclero is, one 
of the main predicti ve fac tors of heart attack 
and troke . 12 
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Figure l:. Structure of lbvone (2-pheny lchr men-4-one), 
the cherruca l backbone o f the ll av noid . Additi on of 
functional groups to tl avont: produce different llav noid . 
For example, reducing the ketone group to a hydrox 1 
y ields a llavonol. 10 Y 
Oxidized LDL is preferentially taken up into 
macrophage and foam cells), which are major 
constituents of atherosclerotic plaques. 13 By 
reducing the oxidation of LDL, flavonoids help 
prevent this accumulation of plaque, decreasing 
morbidity and mortality from CV di sease. 14 It 
eems that only small amounts of fl avonoids are 
needed to achieve their beneficial effects, so 
even occasional consumption of cranberries may 
be cardioprotective. 15 
Ruel and Couillard have also shown that 
there i some evidence for cranberrie improving 
plasma lipid profiles, another strong predictor of 
cardiovascular disease. The evidence suggest 
that cranberries may be able to increase HDL 
and decrea e LDL levels in the blood, but some 
tudies have failed to show a change in serum 
lipid levels.7 
Verdict: Cranberries seem to confer significant 
benefits on cardiovascular health , mostly through 
flavonoid-mediated inhibition of oxidation of 
LDL. Including fresh cranberries or cranberry 
juice in the diet can reduce the ri k of 
atherosclerosis and subsequent events such as 
troke or infarction. However, these benefits 
may not be exclusive to cranberries, as research 
has shown similar outcomes with diet high in 
other fruits and vegetables (such as the 
Mediterranean diet). Con umer should also be 
wary of the advertised benefits of cranberry 
juice. While these juices do contain flavonoids 
and other beneficial compounds, inve tigators 
exclu ively studied the benefits of low-calorie 
juices. Mo t commercial juices are high in sugar, 
which can contribute to obesity and other 
associated health problem . For an effective 
public-health campaign to be built around 
cranberry juice, it must be explicit that fre h 
cranberries and low-calorie juices will confer the 
greatest health benefits. All in all, the data is 
strong suggesting that adding cranberrie to an 
already balanced diet may reduce the onset of 
cardiovascular symptoms. 
Chocolate 
Evidence and Biochemistry: Many news outlets 
have publicized studies demonstrating the 
benefits of chocolate consumption. 16- 18 While the 
reports have been careful to warn against gorging 
on chocolate bars in an effort to stave off 
atherosclerosis, many people may still be 
tempted to add large amount of chocolate to 
their diet, possibly believing that protecting their 
hearts is outweighs the ri sks of excessive junk 
food consumpti on. 
Studies on chocolate and cardiovascul ar 
disease have focused on the effects of dark 
. 19 Th chocolate and cocoa consumptiOn . e 
protective mechanism is similar to that of 
cranberries, with fl avonoids acting as the 
primary cardioprotecti ve agent. Chocolate 
contains large amounts of catechin , which are 
flavan-3-ol flavonoid compound , and 
procyanidins, another cia of flavonoids.20-2 1 
The mechanism mimics that of cranberries, with 
an increa e in anti-oxidant effects inhibiting 
LDL oxidation and preventing formation of 
arterial plaques. 
Studies have also demonstrated that 
chocolate and cocoa consumption can raise 
levels of high den ity lipoproteins (HDL, the 
"good cholesterol"), which has been shown to 
decreased susceptibility to cardiac events. 22 
Increased HDL levels have been hypothesized to 
suppress LDL oxidation by one of several 
mechanisms including inhibition of monocyte 
chemotaxi leading to decreased 
atherosclerosis23 and direct hydrolysis of lipid 
peroxide? 4 Some studie , however, have failed 
to demonstrate ignificant change in HDL:LDL 
ratios, o chocolate alone hould not be used to 
treat lipid disorders. An average increase in HDL 
level of 4% and 8% longer lag time in LDL 
oxidation were observed in patients on an 
average American diet supplemented with 16g of 
dark chocolate and 22g of cocoa powder per 
day. 19 
Verdict: Medical consensus holds that chocolate 
and cocoa can protect against cardiovascular 
disease, likely via flavonoid-mediated LDL 
antioxidation and increased HDL levels. 
However, the observed effects on the serum 
lipids were relatively minor -hardly ufficient to 
counter the fact that chocolate i a high-fat, high-
sugar food lacking the overall nuttitional value 
of other rich flavonoid sources such as fruits and 
vegetables. Expetimental studies focused only on 
dark chocolate and cocoa consumption (not other 
varieties, like milk chocolate) and were careful 
to study diet similar to a standard American diet 
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in nutritional value and calori c intake. Thus, 
adding chocolate to the diet without eliminating 
an equi valent source of calories and maintaining 
proper nutrition has not been hown to improve 
health and intui tively seems likely to contribute 
to poor health through increased weight and 
adi pose build-up. Our recommendation is that 
dark chocolate or cocoa may be consumed to 
prevent heart di sease, but onl y a part of a 
balanced, nutritional diet. While (arguably) less 
enjoyable, it may be more beneficial to overall 
health to seek a different source of fl avonoids, 
such a frui ts and vegetables. 
Dairy Products 
Evidence: Milk con umption has traditionall y 
been associated with increased cardiova cular 
disease due to its high cholesterol and satu rated 
fat content,25 which have been cau all y linked to 
atherosclerosi .12 However, everal 
epidemiologic studie have demonstrated 
reduced risk of athero clerosis with increased 
milk intake.26-27 Further evidence fo r 
cardioprotective effects of dairy foods co mes 
fro m the o-called "French paradox;" the typical 
diet in France is high in saturated fat and 
cholesterol, but the citizens tend to have a lower 
incidence of heart disease. 28 The e data suggest 
that further con ideration of dairy product a 
protective against cardi ovascul ar di ea e is 
warranted. 
One hypothesis fo r milk ' s 
cardioprotection is that it reduce su ceptibility 
to the metabolic syndrome, which can lead to 
cardiovascular di sease. 28 The World Health 
Organization defines metabolic yndrome as 
glucose into lerance, im paired glucose tolerance 
or di abetes mellitus and/or insulin re i Lance 
together with two or more of: blood pre . ure 
above 140/90, hi gh pl as ma tri glyceride and/or 
low HDL, central obesity and 
0 lb 0 0 29 m1croa ummun a. 
Several studies have hown in verse 
relationships between dairy food consumpti on 
and all aspects of the metabolic syndrome. 30-32 
The e studies have shown that milk has a 
protecti ve effect in both men and women and 
across populations of differe nt ethnicities and 
nationalities. The incidence of type II di abetes 
mellitus, one of the components of the metabolic 
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syndrome and a disease also characteri zed by 
insulin resistance, was demonstrated to decrease 
with higher dairy intake. The effect was even 
larger if the study participants consumed only 
0 28 33 low-fa t dau y products. · . 
Dairy foods may also prevent weight 
gain, and might even promote loss of abdominal 
fat. 34 This would , in tum, reduce the risk of 
obesity leading to onset of metabolic syndrome, 
which would prevent the resultant cardiovascular 
disease. One explanation for this effect holds that 
dietary calcium may play a role in regulation of 
energy metabolism.28 Dairy foods can al o have 
antihypertensive effect , as eating 35 or more 
ervings of dairy per week halved the 10-year 
ri k of developing hypertension as compared to 
eating 10 or fewer serving in the CARDIA 
study.30 Thi effect may result from peptide 
produced by lactic acid bacteri a present in milk 
product inhibiting ACE enzyme and endothelin 
l kn "h 0 35-36 re ease, two r own anti ypertenstve agents. 
Verdict: Even though dairy foods contain 
ignificant amount of CVD-promoting fat and 
chole terol, the evidence uggests that dairy 
products are actually cardioprotecti ve. The 
dramatic re ult of the CARDIA tudy how 
significant antihypertensive effec ts, though it i 
unrealistic to expect people who would not 
otherw i e do so to eat 35 or more ervings of 
dairy food per week. However, even moderately 
increas ing dairy consumption can be beneficial. 
Dairy food al o play an important role in 
protection from metabolic syndrome and type II 
diabete . Low fa t and skim milk and yogurt seem 
to have the most pronounced effects, and people 
wishing to increase their dairy con umption 
should foc u on the e foods. Though the 
evidence is strong for dairy products' benefits, it 
is important to remember that dairy foods will 
not protect against C VD in the ab ence of other 
interventions like a balanced diet and acti ve 
lifestyle. 
Omega-3 fatty acids 
Evidence: Of all the dietary elements claimin o 
b 
cardiovascular benefit , few have garnered more 
attention than omega 3 fatty ac ids. Egg , bread, 
yogurt and other foods are fo rtif ied with the e 
compounds and display attention-grabbing labels 
touting their high levels of omega-3. Dietary 
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Figure 2: Eicosapentanoic acid, an example of an omega-3 fa tty acid. Note that the th ird-last carbon i invo lved in a 
double bond.39 
supplements containing omega-3 ' s are also being 
marketed with promises to deli ver improvement 
in health .37 
Omega-3 fatty acid are e ential fatty 
acid naturally present in fish, flaxseed, walnuts, 
canola oil , and soybean oil. They are o named 
because they are characteri zed by a double bond 
beginning at the third-last carbon atom in their 
chain , the third carbon from the "omega" end of 
the chain. The three main omega-3 fatty acids 
consumed are alpha-linolenic ac id, 
eicosapentaenoic acid and docosahexaenoic 
acid. 38 
Omega-3 fatty acids have been 
demonstrated to exert antiatherogenic, 
antithrombotic, and antiarrhythmic effects, all of 
which contribute to their prevention of 
cardiovascular disease .40 Investigations using 
many different de igns have linked omega-3 
fatty acid and fi sh consumption to reductions in 
cardiovascular disease. Epidemiologic studies 
include the Health Professional Follow Up 
study41 and the Nurses Health Studl 2 which 
fo llowed 45 ,722 and 76,283 subjects for average 
follow up time of 14 and 10 years, respectively. 
The Nurses Health Study showed a relati ve risk 
of fatal i chemic heart disease of 0.55 for the 
cohort with the hi ghest consumption of omega-
3' s versus the group with the lowe t 
consumption. Other studie and meta-analyse 
have demonstrated inverse relation hip between 
omega-3 consumption and mortality, both all-
cause mortality and that from cardiova cular 
disease (coronary artery disease, MI, stroke, 
etc.) .43-45 
Given the benefit to heart health 
demonstrated by these studies , it is not surprising 
that omega-3' have received huge publicity and 
are potenti ally exploited by dubious companies 
and products. A search fo r "omega 3" on the 
popular search-engine www .ask. com yielded 
links to websites claiming extra benefits fo r such 
products as Norwegian "virgin almon oil."46 
Other ites promote "clean" and "natural" 
omega-3 sources47 and oils deri ved fro m "gently 
pressed" ources.48 Such products typicall y come 
in pill fo rm with recommended do es of up to 3 
per day, ensuring a hi gh cost fo r their continued 
use. 
Verdict: A resounding yes. The evidence is 
extremely strong that including fish and other 
omega-3 sources in the diet, even in moderate 
amounts, can prov ide major benefits in reduction 
of cardiovascular disease. However, there is a 
potential for exploitation and fa l e claims to 
abound due to lack of public understanding. 
Claims of special efficacy from certain types or 
sources of omega-3 and claims that intuitive ly 
unhealthy foods like bacon are actually healthy 
should be ignored. Nevertheless, fish and other 
omega-3 fortified foods like eggs and yogurt 
should be added to the diet of heart-conscious 
people. The American Heart Association and 
World Health Organization both recommend two 
serving of fi sh per week, especially oily fi h 
like salmon , tuna, and trout. Diets such as the 
Mediterranean diet49 are good sources of 
guidance for incorporating omega-3 fatty acids 
into a health y diet. 
Conclusion 
Diet plays a powerful role in cardiovascular 
health , but this will not come as news to most 
people. However, certain foods seem to confer 
more benefit than others, whether by changing 
lipid profiles, moderating the metabolic 
syndrome, anti-thrombotic effects, or other 
mechanisms. Strong ev idence backs cranberrie , 
dairy foods, chocolate, and omega-3 fatty acids 
as protective against cardiova cular disea e. A 
few studies received funding or other upport 
fro m corporations with interests in the 
S lt 3, 11 .30 h" h . 1 f b" re u s w IC create a potentia or 1ase . 
However, the vast majority of tudi es cited in 
this paper did not declare any competing 
interests and the evidence remains strono 
b 
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supporting the cardioprotective effects of the 
aforementioned food . 
These effec ts demonstrate that what we 
eat can powerfull y impact the health of our 
hearts. However, it is important not to overstate 
the impacts that the e foods can deliver. After 
surveying the evidence, a Starbucks Mocha Latte 
may seem to be a new "superfood"- after all, it 
contains chocolate and caffeine fo r antioxidants 
milk fo r calcium, and health y fa ts. But th a~ 
doesn' t cancel out the sugar and unhealth y fa t 
assoc iated with tho e beneficial compound . No 
single food will prevent heart di ease nor i 
adherence to every new guideline required to be 
protected, but modem research continue to 
support Hippocrate ' idea that food ha the 
power to heal. Regular exerci e and a balanced 
diet including some of the food di scussed in thi s 
article will go a long way toward maintaining a 
healthy heart. 
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History of Medicine 
History of the Circulatory System: discovery of the basics 
Adam Garber, Medicine 2010 and Michael Livingston, Medicine 2011 
Reviewed by Dr. Vivian McAlister 
Today, the fi eld of cardiology i understood a a highl y evolved and mature pecialty of medicine. However, the 
journey toward our current gra p on the subject ha been a long one. T he discovery of the most basic heart phy iology 
and anatomy ha a hi Lory of more than two millennia. This paper d i cus e the development of the most fundamental 
principles of heart phy iology and anatomy whi le outl i ning the influential context of their origin . 
The fie ld of cardiology ha long been perceived 
as a highly sophi ticated arena of understanding 
wi th phy iologically intricate problem and 
technologically advanced oluti ons. And though 
it i j u t that, it was not alway o. In the greater 
timeline, cardiology a a medical pecialty i till 
in it in fancy. More o, cardiothoracic urgery 
remained a fie ld unborn until after World War II, 
making it the tardiest of urgical specialties by 
twenty year . 1 The study of the human heart in 
general ha had a much longer history with 
fa c inating acceleration , tediou plateaus, and , 
at times, di appointing regressions. But the 
history that is di cus ed herein is the history of 
that part of cardi ology that most people, scienti t 
or not, take for granted a obvious knowledge; 
this is the understanding of the most ba ic 
principles of the circulatory system. 
I begin at the end o f thi s hi story by 
ummari zing its accompli shment. The heart i a 
pump. lt contain four chamber . The ri ght ide 
of the heart pump blood to the lung where it 
pick up oxygen and then enter the left ide of 
the heart. The oxygen-ri ch blood in the left side 
of the heart i separated fro m the oxygen-poor 
blood in the right ide of the heart by the 
interventricul ar septum. The oxygen-ri ch blood 
is pumped through the left ide of heart to the 
entire body by arteri es where it upplies the 
di fferent ti s ues with oxygen. Oxygen exchange 
occurs in the smalle t ve se ls called capillari es 
and oxygen poor blood ubsequently is carri ed 
back to the right side of the heart by vein .2 
The mo t bas ic principles of the 
circulatory system took thousands of year to 
uncover. An Egyptian papyru dating back to 
l500BC correctl y correlated the character and 
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frequency of the pul e with the patient's health 
status. Hippocrate (460-355BC) and his pupils 
also drew accurate conclusion regarding the 
nature of blood flow. One pupil described the 
perpetual movement of blood "with courses of 
ri ver returning to their ources after a passage 
through numerou channel ". 3 However, this 
concept of circularity would only be confirmed 
two millenni a later by William Harvey. It wa 
Ari to tl e, the anatomi t, philo opher, and know-
it-all of the time who began the di ruption of 
cientific under tanding of the heart and its 
y tern. While orne of hi physiological ideas 
bore orne value, he al o committed the 
academic di ervice of attributing the eat of 
body intelligence' and the ource of body heat to 
the herut 4 . Such exaggeration of the heart 's 
function in the body was mirrored by 
Erasistratu (c. 3 10-240BC) who first described 
the heart ' valve , and expla ined that air entered 
the heart fro m the lung where it was 
transformed into 'pneuma', the vital pirit, 'a 
most ubtle vapor' to be carri ed to the body by 
arterie . 1 Only ve in , he eiToneously conceived, 
contained blood. 
So, fo r a peri od of 500 year little 
advance was made in the under tandin o- of the 
c 
c irculatory system. However, the under tanding 
of our world and all thing in it was forever 
changed with the birth of Chri ti anity and it 
populari zation. Indeed, the nex t advancement in 
circul atory phys iology came from Galen (c. AD 
130-200), whose work was viewed favourably 
by the Church. Galen, though not Chri ti an, was 
monothei. tic and hi wor hip of one god , 
Aesculaplll s, the god of medicine, haped hi 
theories in uch a way that they were compatible 
with the views of the Church. The Church was, 
at the time, fi ghting Roman polythei m and so 
Galen' s worship of a single God who created all 
things for a purpose was agreeable enough. 1 
ln brief, Galen fo und that arterie 
contained blood, in tead of air a had been the 
belief to that point. He conceived of two 
ystems: the venous system which was 
nutritionally relevant, and the arteri al system, 
which was responsible fo r body heat. Included in 
his theories are the belief in the existence of 
pneuma, the vital spirit on which life depends as 
well a two other spirit , the ' animal pirit ' and 
the ' natural spirits' . Galen falsely connected 
these two ystems of the ri ght and left heart by 
supposed pores in the interventricular eptum. 1 •4 
Galen' theories were more thorough and 
complex than detailed in this essay. His views 
were intricate enough for the critical scientist, 
compatible enough with the Church, and 
mystical such that it enreuraged the 
philo opher's under tanding of the heart as the 
seat of the soul. As a result, his views went 
largely unquestioned fo r a staggering 1500 
years! 
The fir t physician to question Galen ' 
views was Ibn An-Nafis (1210-88), whose work 
made the first reference to the pulmonary 
circulation. However, this knowledge was likely 
lo t until this same finding was independently 
di covered three centuries later by Servetus, a 
Unitarian, who was rewarded for his science and 
his anti-Protestant belief by John Calvin in 
Geneva, who had him placed on a stake and 
burnt to the core. 1 The initi al anatomical 
understandings of the heart were dispersed, lo t, 
or destroyed purpo efully and, throughout the 
Dark Age , human dissection was either 
disallowed or difficult to carry out due to certain 
impo ed ecclesia ti cal edicts.5 Leonardo da 
Vinci (1452-1519) took great interest in the 
anatomical structure and physiological workings 
of the heart. He correctly drew the heart with 
four chambers and, through experiments, 
described the mechanism by which the aortic 
valve closed. 6 Andreas Vesalius (1514-64) also 
possessed a passion for dissection and partook in 
the illegal yet common, practice of body-
snatching. In his work, "De Humani Corpori 
Fabrica", he carefully, but strongly, questioned 
Galen's view , which were taught in the chools 
of medicine du ri ng his time. 
With Galen's views beginning to turn 
obsolete, many ph ysiological questions of the 
heart were reopened. In 1574, Fabriciu of 
Aquapendente (1537- 16 19), publi hed "De 
Venarum Osteolis" which examined the valves 
of veins. He aptly de cribed the valves a ' the 
little doors of the veins' and proposed that they 
'delay the blood and so prevent the whole of it 
flowing to the feet. .. and collecting there ' .4 But it 
was Willi am Harvey (1578- 1657) who finall y 
deconstructed the false views of the 
cardiovascular system. Hi s, "De Motu Cordis", a 
short book dedicated to King Charle I, 
compared the ' king in his kingdom' to the heart 
in the contex t of the body.1 This wise maneuver, 
which praised the King whom he and many 
admired, perhaps aided in his avo idance of harm 
for his publication of contrary views. Through 
his lectures and in his publication, he explained 
that blood pumps with ventricular contraction 
through the lungs back to the heart and then 
through the body where it ' passe through pores 
in the flesh' and returns fro m the periphery 
through veins increasing in size as they approach 
the heart. ~ He specified that blood moves, ' as it 
were, in a circle' and ' th is is the only reason fo r 
the motion and beat of the heart' .4 He 
emphasized that the heart is no other thing but a 
pump as if to crush the spiritualistic functions 
impo ed on the heart until that time. Finally, 
Marcello Malpighi (1628- 1694), Jacob van 
Swammerdam (1637-1680), and Anthony van 
Leeuwenhoek (1632-1723) used the microscope 
to explain the shape of the red blood cell and the 
capillary networks that form the connection 
between arterioles and venules.4 
So, over a great many years the myth of 
the heart were dispelled and the truth came to be 
accepted like in mo t cases of di covery, slowly 
and with much dissent. Yet the heart remains an 
eternal symbol. A ubiquitous metaphorical fo rce 
made reference to by the holiest of books and by 
the most lucrati ve of commercial recording 
artists. In Genesi 6:6 God i described a 
possessing a symbolic ' heart ' when he decides 
that a great flood is in order, "And the LORD 
was orry that He had made man on the earth 
' 
and He was grieved in His heart" . 7 God who has 
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no other body part, but perhap for a guiding 
' hand ', must also pos e a ' heart ', an enigmatic 
box of emotion. More comicall y, Tom Waits, the 
guttural crooner, explains that he has a "bad liver 
and a broken heaLt" .8 While cocktails and the 
like may have done the job on his li ver, it was 
an emotional cocktail of ort that hanned hi s 
heart. The liver's problem i phys iological but 
the heart 's is of a different nature. The ' heart ' a 
a human-constructed ymbol is an entity which 
attempt to tran cend it physio logical function 
and touch on the intangible a pects of what it i 
to be hu man. T hen is it so urprising that with 
all of this attached ymbolism, the academic 
uncovering of the function of the heart took a 
long a it did? It wa a lot to lose and yet, the 
ymbol ha never been lost at all. 
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Medicine and the Internet 
Computer-assisted learning-teaching clinical skills in cardiology 
Jordan Glicksman, Medicine 2010. Pencilla Lang, Medicine 2011, and 
Dr. Kevin Fung, Department of Otolaryngology 
Reviewed by Dr. David Masse/ 
Cardiology i a diver e and ever-expanding field of medicine. Medical trainees mu t master a wide variety of skill 
and knowledge in order to become proficient at managi ng patient with cardiovascular conditi ons. Computer-assisted 
learning has the potential to enhance medical teaching in card iology by providing tudents with an enriching 
interactive learning environment. 
During medical school , student are expected to 
develop a trong foundation of clinical skills. In 
many centers tandardized patients are used to 
teach and evaluate students as they have been 
hown to be an effective teaching method. 
Cardiology, like many areas of medicine, is a 
diverse and ever-expanding field. Advances in 
technology have made many tool available to 
clinician to diagnose and manage patients with 
cardiova cular conditions. Despite the 
availability of equipment such as 
electrocardiograms (ECG), echocardiograms 
(ECHO), physicians till rely heavily on basic 
clinical skills uch as history and physical exam 
to determine the nature of a patient's illness 1• 
While traditional teaching method are helpful 
for teaching students basic eli nical skills, 
multimedia computer technologies provide 
students in the 21 t century with an opportunity 
to refine their talents. 
The Current Use of Multimedia Teaching 
Tools 
Medical educators already ultilize multimedia 
computer technologies to provide students with 
increased exposure in their respective field . The 
Computer-Assisted Learning in Pediatrics 
Program (CLIPP) has already been implemented 
to augment medical education in pediatric _2 
CLIPP is a computer-assisted learning (CAL) 
program that provides students with a 
multimedia experience to case-based learning. 
Programs like CLIPP are gaining popularity, as 
they allow students to learn at their own pace. 
This can allow for tudents to learn at a time and 
location that is convenient for them, as long as 
there is a computer available to work at. 
Advantages of CAL in Cardiology Clinical 
Skills Teaching 
CAL application are of particular value 111 
cardiology teaching due to their ability to 
provide students with information in an 
interactive manner. In a traditional teaching 
etting, students may be taught during a didactic 
teaching seminar (and subsequently memorize) 
that an aortic stenosis murmur is a sys tolic 
ere cendo-decrescendo murmur. This 
information may be reinforced in a clinical 
methods teaching seminar. However, without 
actually hearing the sound themselve , can 
tudents truly appreciate the sound of such a 
murmur? Furthem1ore, will students be able to 
apply this knowledge to a patient that present to 
them during their training or in their future 
practice? 
CAL allows students to learn in a truly 
enriched self-directed learning environment. 
Physical findings such as au cultation may be 
conveyed as they would naturally be ob erved by 
the student. Heart sound from patients with real 
findings may be recorded with electronic 
stethoscopes and then can be incorporated into 
the CAL program. Additionally, the programs 
may make use of other tools such as ECHO and 
ECG findings to allow the learner to correlate a 
patient 's findings into a broader picture and help 
reinforce the content. 
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Costs of Implementation 
While the multimedia approach that CAL offers 
is exciting, as with any new technology, cost can 
be concerning. Nevertheless, widespread use of 
CAL modules can be very cost-effecti ve For 
example, in 2005 , the average development cost 
per CLIPP ca e session was approximately $6.2 
Thi s amount will decrea e as the number of 
students using the program increase . Replac ing 
traditional teaching method with CAL has the 
potential to free up the time of medical school 
lecturer to teach in other capacities, such a 
small group ses ion . Furthermore, CAL has the 
potential to enhance teaching at di stant locations 
uch as satelli te campu es, rural setting and in 
developing nations. 
CAL and Other Learning Methods 
Adult have been hown to learn optimally in 
self-directed learning environments? As a result, 
there has been a shi ft away fro m traditi onal 
lecture and eminar-based teaching and towards 
the implementation of more elf-directed 
learning in medical school . In addition to the 
use of multimedia modalities, CAL can help 
guide learning through other fea tures uch a 
qui zzes and learning game . In fac t, many 
info rmal fo rums fo r CAL have already been 
created by students and instructor . For example, 
it i po sible to find video instructions for 
various aspect of the clinical examination on 
YouTube ® and personal webpages. A more 
profes ional fo rum would allow tudents to 
better capitali ze on CAL's advantage . 
Currently, there i debate a to the effecti venes 
of CA L as a teaching modality. Several studie 
have compared the use of CAL to other modes of 
learn ing. Some of the e tudies how thal there i 
no significant di ffe rence in knowledge and s!Ull 
retention between those taught didactica ll y or by 
seminar when compared to tho e taught by 
computer teaching modules, while some tudie 
ugge t that other fom1s of leaching (e.g. didactic 
I ) ' ll . 2 ,_( . 7 ecture are tt supen or. · 
The Future of CAL 
While research continues to asse s the 
effecti venes of CAL in medical education, this 
new learning tool is a ri sing fo rm of medical 
teaching. The Association of American Medical 
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Colleges (AAMC) has established MedEd 
Portal, a peer-reviewed collection of online 
teaching tools. This resource contains a database 
of learning resources that include tutorials, 
virtual pati ent , and case-based learning among 
other medical education resources.8 Not only 
does the MedEd Portal provide easy access to 
CAL modules, but it also provides incentive to 
academic ph ysicians to create more CAL tools 
th rough recogmt10n as a peer-reviewed 
publication. Initiatives such as this will likely 
increa e the production of CAL module . 
The u e of computer-based teaching in medicine 
has the potential to change the way medicine is 
taught to both current and future generations. 
Between the multimedia capabilities of CAL, 
enhancements over current learning modalities 
and increa ed recognition for publishing CAL 
modules there appears to be a bright future for 
computer-a sisted learning. 
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Medicine and the Law 
Medical Malpractice Litigation: Myth or Growing Crisis? 
Abdullah Alabousi, Medicine 2011 
Reviewed by Dr. Mark Speechley 
One of the most ta lked about is ues in health care, and one that receives much media coverage and public attention, is 
medical malpractice litigation. Opinions on how well thi s liti gati on sys tem functions differ, o metimes starkl y, 
depending on who is being asked. In o rder to full y appreciate the extent and complex ity of medical malpractice 
litigation this paper will con ider the de finiti on of med ical malpractice as well a the laws and procedures followed in 
Canada. Moreover, trends in malpracti ce law uits for practi c ing phy ic ians in the field of Card io logy will be u ed a a 
ca e study. Hopefully, by introduc ing the key organi zation and parties in volved and the important trends and 
indicator to watch, thi paper will help the reader be more informed as a complex debate unfolds on the effec ti veness 
of the current system. 
One of the most talked about issues in health 
care, and one that receives much media coverage 
and public attention, is medical malpractice 
litigation. Broadly, litigation refers to the u e of 
the courts to enforce a right, and request a 
remedy, by one party against another. In the 
context of medical malpractice litigation, the 
legal ' right' being enforced is the right of the 
public to competent medical care - care that is 
free of medical errors that could rea onably have 
been avoided. 1 
Opinions on how well thi sy tern 
functions to protect this right differ, sometime 
starkly, depending on who is being asked. For 
example, some physicians view such legal 
action "a random events that visit unwarranted 
expense and emotional pain on competent, 
hardworking practitioners". 1 Similarly, within 
the North American healthcare industry (the 
hospital sector and insurance providers) there is 
wide agreement that medical malpractice 
lawsuits have become more of a burden than a 
way to ensure patient safety and punish errors 
and carelessness. Even some observers from 
outside the medical system express their concern 
that medical malpractice cases have been altered 
into some form of a "lawsuit lottery" whereby a 
few patients receive hefty compensation, while 
no reimbursement is given to the majority of 
patients injured by medical errors. 1 Nonetheless, 
lawyers and the public, even with all the 
imperfections and equity problems, still view 
malpractice litigation as a way to regulate and 
control "a profession that is unaccustomed to 
external policing". ' In fact, some lawyers 
perceive themselve as "champions of patient 
afety" who are fighting battles with the 
healthcare system on behalf of patients. ' 
This complex and imperfect system of 
malpractice lawsuits has created a significant gap 
between the views of medical professionals and 
the views of their patients. While physicians 
believe they are being unfairly targeted, their 
patient hold the view that legal action is an 
effective way of policing their doctors. ' Legal 
questions that proceed to court inherently 
become adversarial, with lawyer for each side 
hired to defend the intere ts of those who have 
retained their ervice . The inherent adversarial 
nature of these legal contests cannot help but 
obscure the common goal of physicians and 
patients of improving patient ' health , which in 
tum may reinforce mi conceptions and distru t 
and damage the doctor-patient relationship that is 
o important to effective medical care. The 
United States ha 70 percent of the world' s 
lawyers, and five percent of the world 's 
population -- a supply of one lawyer for every 
265 people? Social observers who note the way 
Canada is becoming more similar to the United 
States may see a cautionary tale with respect to 
increased litigiousness in Canada. 
In order to fully appreciate the extent and 
complexity of medical malpractice litigation it is 
important to consider the definition of medical 
malpractice as well as the laws and procedures 
followed in Canada. Moreover, trend in 
malpractice lawsuits for practicing physicians in 
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the field of Cardiology will be used a a ca e 
study. 
What is Medical Malpractice? 
Although di cuss ions involving malpractice 
li tigation can invo lve complex legal 
technicalities, there is a fairly inclusive and 
widely agreed upon defini tion for medical 
malpractice. M uch of the d i crepancy in the 
views of the d iffe rent parties to the e di pu tes 
can then be understood as d isagreement over 
which events and occurrence fa ll under this 
broad defin ition , and whi ch do not. 
Medical malpractice can be defined as an 
act or an omission by a health care provider that 
deviates fro m accepted standard of practice in 
the medical fie ld and which cau es injury or 
harm to the patient. 3 Malpracti ce can result fro m 
negli gence, professional mi conduct, 
carele ne , and/or failure to u e adequate levels 
skill or diligence while caring for a patient. To 
determjne and e tabli sh an accepted standard of 
care, comparison is made to typical care offered 
by ph ysicians in the community; in other words, 
compari son i made to standard applied within 
the same geographical area. 
Another matter that fa ll s under the 
category of medical malpractice is failure to get 
a pati ent ' info nned consent. A physician must 
fully info nn the pati ent about the nature of the 
diagno ed condi tion, the range of treatment 
options, and the known major ri k ? of each. It 
i interesti ng to note that when a doctor inform 
a pati ent of the risks associated with a procedure 
or a treatment, they don' t have to ex plain all the 
pos ibl e ri sk . They are onl y respon ibl e for 
ex pl aining those ri sks that a ' rea onable ' pati ent 
would want to know before makin g their 
decis ion. In addi tion, even if the practitioner 
does not prov ide the ir pati ent with all the 
informati on, the phy ic ian will not be li able if a 
' reasonable' person in the ir position would have 
agreed to the proposed treatment or procedure 
anyway, even if the physic ian had g iven them all 
the information.3 
Thi ex tensive and broad definiti on of 
medical malpractice leaves many issue open to 
the interpretation of judges, juries, and lawyers. 
This leaves much roo m fo r inequality and 
inconsistency in judgments and compensation 
UWOMJ 77(2) 2008 28 
for patients. Physicians are taught to understand 
the considerable amount of uncertainty that 
accompanies diagnosis, and appropriate 
treatment but members of the public may not 
' fully appreciate that medicine is not an exact 
cience and that doctors are not able to make the 
' 
correct diagnosis every time. Doctors may order 
the appropriate te ts and procedures and follow 
the standard of care in a given location and still 
make either no diagnosis or, in some cases, the 
wrong diagnosis. If a phy ician doe all that i in 
the ir power to help the patient, and still 
misdiagnoses a pati ent, are they liable, and is thi s 
considered malpractice? Depending on who 
interprets the law and the definition of 
malpractice, a phy ic ian may in some cases be 
till taken to court even after following the 
appropriate standards of care. 
It i imperfec tions such as the one 
menti oned above, which are a cause of concern 
fo r ph ysic ians and the health care industry. It is 
very important to keep in mind that because of 
medical uncertainty, doctors cannot be 
guarantors of the ervice which they render with 
one hundred percent certainty. A physician is, 
however, legall y required to have the necessary 
know ledge and ex peri ence to perform the 
ervice in que tion. Further, doctor mu t 
exercise the ki ll and care that other in the 
co mmunity u e when dealing with imilar 
ituations. 
The story in Canada 
The medical malpracti ce litigation c risi has not 
reached the everity seen in the United State .4 
The complexity of the ituation there will be 
di cu ses later in the artic le. In the meantime it is 
important to appreciate that takin o- leo-al action b b 
with re pect to medi cal malpractice cases is 
much more difficult in Canada when compared 
to the United State and even the United 
Kingdom.4 In fac t, "Canadian judges tend both 
to be more reluctant to find breach of medical 
standard of care, and to require more exactin o-
proof of causation".4 o 
.. In . addition, defence of practi cing 
phys1ctan ~~ Canada is killfully managed and 
generously fmanced by the nonprofit Canadi an 
Medical Protective Association (CMPA), a 
mutual defence a sociation of phys icians.5 The 
CMPA, founded in 1901, is funded and operated 
on a not-for-profit bas i by physicians. The 
organization has more than 71 ,000 member 
comprising about 95 per cent of the doctors 
licen ed to practise in Canada.5 The CMPA will 
do all that is in its power and will in ves t heavily 
in defending any phy ician action that is in any 
way defen ible. The organization's main aim i 
to prevent the setting of medical malpractice 
precedents that could cause irrever ible damage 
to the profess ional reputation of the medical 
profession as well as long term financial 
burdens.4 The CMPA's contract with their 
member physicians is for unlimited coverage, 
with few exceptions. Some of the exclusions 
include cases involving ethical violations by a 
physician, uch a sexual mi conduct; in such 
circumstances the CMP A will not cover the 
physician but will provide them with defence 
counsel and advice.4 
In term of medical malpractice litigation 
in Canada, there are a number of trends that need 
to be discussed. These trends include the rate at 
which legal action is taken against practicing 
physicians, and the cost of malpractice insurance 
in the country. 
On the positive side, the CMPA has made 
it clear that legal actions against physicians have 
declined over the past decade from about 26 per 
1000 members in 1996 to 13 per 1000 members 
in 2006.6 In other words, practicing Canadian 
physicians today are half as likely to be involved 
in medical malpractice lawsuits than they were 
10 years ago. This maybe interpreted as resulting 
from a growing emphasis on patient safety and 
ri sk management by doctors, or it can be seen to 
have resulted from a more extreme approach of 
the CMPA in the pa t decade to preserve the 
profes ional reputation of medicine. 
However, while the rate of litigation 
against Canadian doctors has been declining, 
there are other trends that are quite troubling. For 
instance, the cost of medical liability ha 
increased signi ficantly over the past decade, with 
annual damages and legal and expert 
administration costs rising from about $ 170 
million in 1997 to more than $400 million by 
2006. The median damage cost increa ed from 
about $30,000 in 1996 to nearly $ 100,000 in 
2006.6 
In addition, the CMPA has identified a 
trend of "increasing intru sions on a physician' 
right to due proce s in the name of patient 
safety".6 However, these claims are subj ective, 
may be bi ased , and are difficult to verify without 
the involvement of an independent entity that 
does not have special interest in the issue of 
medical malpractice litigation and their 
outcome . 
Another troubling trend, which does not 
seem to be affected by the decline in legal 
action again t physician , i the rising cost of 
malpractice insurance in Canada. Over the past 
decade there has been a steep increase in the cost 
of malpractice insurance in the coun try that is 
beginning to have a ignificant effect on 
practicing physicians. It has been estimated that 
as of 2001 , average insurance rates in Ontario 
had climbed by nearly 45%, while rates in 
Manitoba, Saskatchewan, and Alberta had had a 
more modest increase of 11 % by the same year.7 
And, since Canada in general, and Ontario in 
particular, ha a worrisome physician shortage, 
the significant increase in malpractice insurance 
fees in some provinces may put these 
jurisdictions at a disadvantage when recruiting 
and retaining doctors.7 Although most specialties 
are being affected by the insurance fee hikes, 
some specialtie such as Orthopaedics, 
Neurosurgery, and Obstetrics have been more 
significantly influenced. 7 
These figure clearly upport the view 
that there ha been an increase in malpractice 
insurance fees in Canada and the awards in 
malpractice court decision . However, contrary 
to popular belief and the selecti ve media report 
describing the high-profile, high-cost cases, the 
perception that Canadian doctors are maki ng 
more mi takes and that they are more likely to 
get ued than in the pas t is false according to 
research conducted by the Canadian Health 
Services Research Foundation (CHSRF).8 In 
reality, the number of medical malpractice 
lawsuits filed in Canada peaked at 1,4 15 in 1996, 
and has been on the decline since.8 Furthermore, 
an increa ing percentage of lawsui ts that went to 
trial concluded with j udgments in favour of the 
physicians, from 73% in 1994 to 82% in 2004.8 
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Malpractice in Cardiology 
After considering the general concerns with 
medical malpractice litigation in Canada, we will 
now go on with a brief overview of issues with 
medical malpractice in the fi eld of Cardiology. 
E ven though there is a plethora of information 
pertaining to medical malpractice liti gation in 
general, it wa very di fficult to find Canadi an 
data pertaining pecifically to the fi eld of 
Cardio logy. However, the American College of 
Cardio logy prov ides some information that can 
be used to get a general idea about what is 
happening within thi s field of medicine in North 
America. 
Just as in other medical specialties, 
medical malpractice litigation has been a key 
area of concern for Cardio logists. Costs of 
medical malprac tice insurance have been 
increa ing rapidly, and the rates for doc tors in 
Cardiology are consistent with those in other 
high-ri k specialties. 9 This has had a significant 
effect on the li velihood of such phy ic ian , and 
has even fo rced orne of them to leave their 
practice. Thi trend has been een in the United 
State , but presumably the situation is similar yet 
probably not as ex treme here in Canada. As for 
the causes behind thi increase in premiums, they 
are pre umably simil ar to other pecialtie in that 
they include "fri volous lawsuit and exaggerated 
monetary award ", in addition to the exodus of 
o rne major insurance carri ers from the market. 9 
Future Outlook 
At thi s point in time, the future outlook for 
phys icians is bleak at be t. Medical malpracti ce 
insurance premiums are still on the ri e, and 
monetary award in the cases where the ruling i 
in favo ur of the patient are rapidl y increas ing. 
The only bri ght side to all o f this is the fact that 
there has been a decrease in the rates at which 
physic ians are being sued. However, that has not 
been enough to slow down the trend of 
increasing insurance fees . 
The question that come to mind at this 
point is who reall y is responsible for the c ri si ? 
And if more than one party is responsible, then 
will any of them stand up and do something 
about it? Should the government attempt to 
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reform the laws to better protect both doctors and 
patients? What is the evidence that patient safety 
is actually improved by the pre ent system? 
Should the medical profession cease to be 
regulated by the physicians themselves? Should 
physicians accept a greater role by the 
government in policing the medical profession, 
in exchange fo r legal protection against frivolous 
and unreasonable legal actions? What if anything 
can be learned from other countries? These are 
all complex questions, with no simple an wers. 
Hopefull y, by introducing the key organizations 
and parties in vo lved and the important trends 
and indicator to watch, this paper will help the 
reader be more informed as thi s complex debate 
unfold . 
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Dr. Richard J. Novick on Guns, Germs and Steel- Perspectives from a Cardio-
Thoracic and Transplant Surgeon 
Alysia Zhou, Medicine 20IO 
Reviewed by Dr. Richard Novick 
I was a medical tudent on surgery at the Royal Vic [in Montreal] one ni ght when I got a stat page to go down to 
emerg. In emerg there was a policeman who had been shot down on Peel St. at the jewelry store where he came across 
a robbery. The guy wa lyi ng on the s tretcher, hi eyes ro lled back, hi blood pressure wa 50, there was blood 
spurting out from his chest - it was a to tal nigh tmare situation and I was the only one there. So I said, "Get the surg ical 
chief res ident; get the attending." I put an IV in thi s guy o I fe lt proud about that; they intubated him . The Chief 
re ident came a minute later, got on the phone and sa id, "Get me an OR." 
We went up the e levator and in the meantime the policeman arrested o we started CPR. As we entered the 
OR, I wa sitting with my knees on the bed and pumping on his chest while blood was pouri ng out a ll over the place. I 
was so tachycardic my pulse was throbbing in my ears. Paul (the Chief resident) opened the chest and the guy was 
sti ll fibrillating so he opened the pericardium and massaged and zapped him internall y. He came back but hi s BP wa 
just 50 and there wa black blood spurting from his right ventric le . Paul aid, "Give me a 2-0"; he took the 2-0 
prolene, put it into the RV and turned to me: "Novick take this driver." I wa holding this driver and shaking like a leaf 
and he said, "When I put this needle through, you grab the tip of the needle and you bring it through." So he put the 
needle through, I grabbed it and the policeman fibrillated agai n; we defibrillated and blood was still pouring out. The 
second needle came through, I grabbed it, Paul tied a knot and the bleeding stopped. This wa a young man who 
didn ' t have coronary disease and all of a sudden the BP was 78 , 80 ... So we stood there for about an hour irrigating 
and closing the policeman. after which we brought him to the unit. Of course he had every complication under the sun ; 
his kidneys failed and he needed dialysis but six weeks later he walked out of the ho -pital in excellent shape. That was 
one of my first nights on call in surgery and I wa there for his whole hospital stay. 
Not short of an episode one would see on the 
television series E.R. , this was, however, a real-
life pivotal experience for a young third year 
medical student and now Chief and Chair of 
Cardiac Surgery, Dr. Richard J. Novick. 
With a 42-page curriculum vitae 
detailing over 125 publications, numerous 
appointments, grants and awards, as well a 
knowing six languages, Dr. Novick is truly a 
renaissance man . Born and raised in Montreal, 
Quebec, his talents were fostered by a liberal 
arts philosophy instilled in him by his parents of 
the importance of having a broad education. He 
grew up in a "medical hou ehold" and hi s father 
still practices otolaryngology in Montreal at age 
84. True to this broad education of philosophy, 
Dr. Novick took a path less traveled and 
pursued a degree in Philosophy at Brandeis 
University in Boston, with a minor in biology. 
His honors thesis wa an analysis of the original 
works of Jean-Paul Sartre 's theory of 
existentialism. 
Towards the end of the 3rd year of his 
undergraduate studies, Dr. Novick knew that 
decisions had to be made about what to pursue 
after his Bachelor's degree. To keep his options 
open, Dr. Novick wrote the MCAT, LSAT and 
GMAT exams. After much personal reflection 
and di cus ion with his family , Dr. Novick 
decided medicine was his true calling. 
Ironically, Dr. Novick started medical school at 
McGill Univer ity in the fall of 1976 in the 
same class as hi younger brother of 15 month , 
who pursued a pre-medical education at McGill 
and was focused on medicine at a young age: 
I had the bare minimum of sciences, so the first 
few months of med school were torture for me: 
pretty much the only reason I survived was: 1) I 
worked very hard, and 2) my brother helped m.e. 
He had done anatomy, histology, and 
physiology the year before. When I looked under 
the microscope, I had no idea -.,vhat I was 
looking at. I had never looked under a 
microscope before in my life; even in biology in 
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College it was all conceptual learning. By the 
middle of first year, however, everyone was ort 
of the sam.e in terms of their knowledge base so 
those of us from a non-science background 
caught up pretty quickly. 
When asked on how he decided during medical 
chool that surgery was his pass ion, it often 
came down to the clinical experience , the 
teachers and mentors he encountered throughout 
his medical education, and keeping an open 
mind throughout hi clerk hip year. For 
in tance, Dr. Nov ick came into medicine 
con idering psychiatry to be an area of intere t 
because of hi undergraduate and volunteer 
ex perience related to psychology, a we ll as 
having a mentor in the fie ld. 
During medical choo l, Dr. Novick 
excelled in variou fi eld of medicine, including 
winning the Franci William Prize for the 
highe t achievement in Internal Medicine. Hi s 
clerkship year al o brought him into contact 
with Dr. L. D. Maclean, Chief of Surgery at 
McGill, who became Dr. Novick 's mentor 
throughout hi urgery rotation. Thi , combined 
with eminal event that occurred during hi 
urgery rotation at the Royal Victori a Hospital, 
helped Dr. Novick narrow hi area of interest 
and " o after that ex peri ence psychi atry wa a 
negati ve and surgery, although intense, wa 
pretty pos iti ve." 
With electi ve time and the res idency 
match looming, Dr. Nov ick requested a cardiac 
surgery e lecti ve and wa launched into another 
life-changing ex peri ence: 
I had the good fo rtune to spend a month as a 
medical student on cardiac surgery. It was Dr. 
Tony Dobe/l who was the second surgeon to 
mentor me. He was Head of Cardiac Surgery at 
the time and a world-renowned pediatric 
surgeon. He also did a f air number of adult 
cases and he took m.e under his wing. The most 
amazing thing with Dr. Dobell was that no 
m.atter how bad things got he would always stay 
calm. For example, there could be a hole in the 
aorta with blood flying past his head and he 
would just put his finger on it and ·ay, "A lit1le 
bit of mild oozing here- maybe I'll take a 4-0 " 
and put the 4-0 through and solve the problem. 
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It was almost as if it was just a little scrape. So I 
decided in the beginning of 41h year that I 
wanted to be a surgeon. For m.e, it was 
undifferentiated initially, and then I only 
thought of cardiac surge1y later. 
Dr. Novick decided to apply to the US match 
becau e he wanted a broad and intense 
ex perience. He therefore applied to numerous 
American in titution , "including all the major 
kni fe and gun clubs." He subsequently matched 
to Bellevue Ho pital and the New York 
Uni versity Medical Center. 
Moving to New York and embarking on 
what wa to be an "earth -shattering experience," 
Dr. Novick wa thrust into the full intensity of 
hi urgical intern hip from day one. In addition 
to the re pon ibilitie of being a newly minted 
MD, the ' 80 proved to be a high tre period 
for all healthcare worker a AIDS and HIV 
were ju t comjng into the foray of medical 
knowledge. 
Back then, the crime rate were dramatically 
higher in New York City than they are now. It 
was also a cra::_y time becau e people were 
starting to appear with big lymph nodes and 
pnewnocysti pneumonia. AIDS wasn 't officially 
labeled until 19 4 o there were all these sick 
people coming to emerg coughing and 
hypoxemic and a week later they were dead ... It 
was a high ri k time across the board. There 
was no universal precaution and f rankly, we 
were lucky I to not have contra ted disease 
our elve / . 
I was on the I rauma service my first two months 
and on call one in two. During m • f ir t night, 
things got a bit quiet at midnight o I asked the 
ward nurse. " Where i the on call room ?" 
She started laughing and replied, "There's no 
on call room here ... You 're never going to get to 
bed. ·· 
" Well it 's quiet now and I want to go to bed " 1 
responded. 
The beeper then rang and reported, ''Dr. Novick 
there's 23 patients f or you to asses in emerg. " 
There was no sleep; it wa total brutality .... You 
star~ed pre-rounds at 4:30am. the Chief 
Restdent came at 5:30am and expected you to 
take him. around ... There were patients on 5 or 6 
different wards and severaL different ICUs and 
you had to draw the blood and measure cardiac 
outputs yourself, as weLL as know every patient's 
lab value. 
On your night off, you'd get out at 10 or 11pm, 
go to your apartment, have a Little bit of supper, 
crash for 3 hours and then the whole cycLe 
would reswne ... For exampLe, there were two 
days where I didn't eat anything. You 'd see a 
cart of muffins being pushed down the haLLway 
after rounds and Like a rabid anim.al, you would 
grab a donut because you hadn't eaten in 36 
hours. There was no one Looking out for you. 
Drug trafficking and gang violence in the area 
would guarantee Dr. Novick and the hospital 
staff that on every Friday shift at 2:30 or 3am, 
they would have "3 or 4 people shot up very 
reliably" with some coming to emergency DOA. 
The pecking order of the resident would dictate 
who did what in case of multiple gunshot 
victims coming into the hospital: 
There were a couple of times where we had 
three gunshot wounds staggered. So the first one 
I would resuscitate, put the !Vs in, intubate and 
get him. up to the OR and the R5 would be 
opening him. Another one would come in and 
the R3 would open him up so both ORs were in 
progress. And then a new gunshot victim would 
come in and then I had to do the resuscitation, 
sometimes a left thoracotomy to put a cLamp on 
the descending aorta if it was a major 
abdominal exsanguination. That would fairly 
reliably get the patient back but then you'd have 
to get him into the OR with an open chest and 
blood is dripping down the haLLways as you 
wheeled him to the OR. You've then got to prep, 
drape, open the belly, and by then the R5 would 
come over because som.eone else would be 
cLosing the first gunshot wound that came in. 
It was pretty catacLysmic. I did two months of 
training in trauma, and then I had rotations in 
neurosurge1y, cardiac and plastic surgery at 
NYU. I did orthopedics as well at Bellevue. It 
was a real rotating surgical internship and I 
saw everything. 
Most of the trauma populations were pretty 
unsavory people; they didn 't have a healthy 
lifestyLe so I had concerns about getting serious 
disease myself. And then also the sheer intensity 
of it: with 160 hours in a week, I was in the 
hospital for 125 to 130 of those hours. My 
health held up but there were a coupLe of people 
in our group who didn't fare so well. We were 
16 initiaLLy, but one guy took his own life and 
couldn 't handLe it. Another colleague of mine, 
and I was actuaLLy very Lucky, wanted to switch 
caLL with me so we switched on short notice. He 
left the hospital and got stabbed 14 times 
literally m.inutes after leaving and barely 
survived; I had just been talking to him severaL 
minutes previously. So I had severaL concerns 
about my personal safety. 
As Dr. Novick's intern hip was nearing an end, 
an "awkward week, ju t like a pivotal week 
when I decided to go to medical chool" helped 
him in deciding where to pursue hi residency 
training. 
I had, for severaL months, doubts that I really 
wanted to stay in New York and I had just heard 
that there was an opening at the Royal Vic in 
Montreal. The Chief of Surgery. Dr. Maclean, 
had spoken to m.y dad, who still works there, 
asked how I was doing and mentioned that they 
had an opening for a second year surgical 
resident [equivalent to a PGY3 position] 
because of my experience in New York. I was by 
then engaged and my fiance (and subsequent 
wife) Terri was working in Montreal. 
In deciding to return to Canada, Dr. Novick 
turned down the offer of a Chief Resident 
position at Bellevue. During his re idency at 
McGill, Dr. Novick found time to also complete 
his Masters of Science degree in Experimental 
Surgery within cardiac urgery, ' and it was in 
that year that I decided ultimately I was 
intere ted in cardiac surgery." In fact, Dr. 
Novick started in the cardiac surgery program 
without even having a formal acceptance letter: 
I remember very well Dr. Dobell, one of my 
mentors, walking dmvn to the Lab toward the 
end of my research year and said "Richard 
you've been doing great work, you've published 
a couple of papers already, and you 're going to 
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be writing your Master's. Do you want to be a 
cardiac surgery resident in our program?" 
I had been thinking about it for a few months 
and replied, " Well let me speak with my wife." 
Dr. Dobell replied, " Well if you want it it 's 
yours." 
"But don 't you have a selection committee ? 
Don 't I have to fill out an application ? Don 't I 
have to interview?" I asked. 
"Well here, shake my hand'' he responded. So I 
decided to go into cardiac surgery and in fact I 
never had any I'Vritten acceptance letter. But 
back then it was a different time. He gave tne his 
word, he shook my hand and told me I was in 
the program. 
Within a period of 4 years, Dr. Novick had 
written 12 fellow hip exams which included 
Quebec, Canadian and American board exam 
in General Surgery, as well as Cardiac and 
Thoracic Surgery. It was al o a time of rapid 
change in the field of surgery with 
transplantation starting to be offered a a 
treatment for conditions that previously proved 
fatal : 
Those were early days of transplantation but at 
the Royal Vic there was a transplant progrmn 
and a very energetic transplant surgeon, Dr. 
Albert Guerraty ... We would do a transplant and 
I always peJformed the donor run to bring the 
heart back. Usually at the beginning Albert 
would sew it in; sometimes I would at the end. 
During the pivotal first f ew hours after 
transplant, we camped out with the patient and 
we took care of them 2417 f or 3 or 4 days. I 
would do two of the days, Albert would do one. 
It was a cataclysmic experience. We did 9 or 10 
transplants during the time I was at the Royal 
Vic and all survived. 
To further develop hi s clinical and research 
interest in transplant urgery, Dr. Novick, with 
the help of hi s mentor Dr. Dobell , entered the 
transplant fellowship program at Stanford 
University. Following his fellowship , Dr. 
Novick was offered a consultant position at the 
Montreal General (a McGill-affiliated Hospital) , 
but wanted to ee what other opportuniti e were 
available. 
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I sent a bunch of letters around to every centre 
in Canada. Dr. McKenzie from London 
responded and set me up for an interview. My 
youngest sister was a law student at Western so 
I stayed in her Cherryhill apartment. My 
interviews were arranged for the Monday 
morning with Dr. McKenzie, whom I met once 
at a meeting, as well as Dr. John Duff, who was 
Chair of Surgery. So I was at my sister's place 
and we went out .for supper on Sunday night 
when she told me, "I don 't feel so well." 
" What's the st01y, do you have food 
poisoning?" 
"No, no. I have pains. " She explained. 
I examined her and she had rebound in her right 
lower quadrant.. .So I scooped 1ny younger 
sister, who could barely stand up straight, into 
my rental car and brought her up to emerg at 
UH. The general surge1y resident cam.e and 
sure enough she had appendicitis and Dr. Duff 
was on call. I was supposed to have an 
interview with Dr. Duff at 7am on Monday 
morning and here we were past m.idnight on 
Sunday. 
All of a udden I wa n 't a surgeon anymore, but 
rather a family member in the waiting room .. So 
my sister got her appendix out and Dr. Duff 
came to m.e at 2am and said, " We found an 
inflamed appendix, everything 's good. " So I 
asked him. " Would you pref er to have the 
interview now? .. 
"No come back at seven. " 
I remember going back to her apartment and 
having a f ew hour of sleep before the interview. 
I was basically overwhelmed by what was 
available [in London]. First of all, I recognized 
that Dr. McKenzie would be an exceptional 
mentor, which he has been .for the past 19 years. 
The focus back then was transplantation - nwre 
transplants were being done here than in 
Montreal and it was all under one roof Even 
though I didn 't know a soul in London except 
for the people I had just met, I decided to com.e 
here and have never regretted that decision. 
When a ked about what factors influenced him 
to choose to become an academic cardiac 
urgeon: 
Some people wish to be big volume cutters and 
they're better suited for community practice. 
There are others who place primacy on the 
academic m.ission. I also did a Graduate 
Certificate in Clinical Epidem.iology and 
Biostatistics and have always cultivated a well-
rounded practice. I' ve done an intennediate 
volume of cardiac surgety cases but have 
always had grants supporting laboratory or 
clinical research. 
The major difference benveen community and 
academic practice is that with the latter, 1) you 
have to be a teacher to medical students and 
residents. You spend a lot of time with the 
residents; they get to know us and we get to 
know them very well. 2) You have to make a 
valuable academic contribution. That makes for 
a very busy life professionally to the point where 
your career can be all-consuming. 
So balance, i it even pos ible? 
If anyone in my position, for instance, with 
major academic, administrative, and clinical 
commitments tells you they've got a well-
balanced life, they're not being fully truthful. 
But you learn how to cope ·with innumerable 
demands and do the best you can. 
There are several ways to accomplish that and 
one is by delegating. My administrative 
assistant knows the way I approach issues, and 
handles administrative tasks in a proactive 
manner. In addition, my secretary has been 
employed by me since the onset of my practice 
in 1988 and runs a very efficient office. 
Furthennore, the residents and fellows work 
very hard. Academically, we have a clinical 
research associate who is very conunitted and 
knowledgeable. 
Above and beyond the adm.inistrative, teaching, 
research and clinical work, many of us, myself 
included, have a larger responsibility to the 
field as a whole. I was the Associate Editor for 
the Annals of Thoracic Surgery for 10 years, 
which is one of the tvvo major publications in 
our field. Presently, I'm on the Royal College 
Cardiac Surgery exam. committee. 
You need to have a supportive family, and that's 
not only a supportive spouse but also kids who 
understand. You need to have a lot of energy 
and be willing to wake up very early and be a 
rigorously efficient as you can with your tim.e. 
Even with highly capable people to delegate 
work to, it's still a scramble on a daily basis 
and you really don't have much free time. 
Complementing Dr. Novick' role as a leader, 
teacher, mentor and innovator i a clear 
recognition of teamwork and the contribution 
of others in helping the divi sion to succeed : 
There's only so m.uch one individual can do so 
it's basically the team; cardiac surgery is the 
commensurate team sport. 
I'm very proud of our team. at all levels. We 
have state-of-the-art individuals including our 
bedside nurses, perfusionists, our residents who 
work vel)' hard, and of course my fellow faculty 
members, each one of whom has eve f)' rea on to 
be very proud of what they 've accomplished in 
their careers. 
Evetyone has m.ade a major contribution to this 
enterprise. For some the focus is clinical and 
technical excellence in surgery, for other it 's 
research, andfor other it 's teaching. Everyone 
has made a wondeJful contribution, ·which has 
made my job much easier. I'm very proud of the 
team. 
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Thinking on Your Feet 
Atrial Septal Defects in Adults 
Todd Greenspoon, Medicine 2010 and Aiman Alak, Medicine 2011 
Reviewed by Dr. Keith Finnie 
Atrial septa l defects (ASD ) are abnormal communica ti ons between the left and right atria allowing mixing of the 
blood between the e two compartments. ASD are the econd mo t common congenjtal lesions in adults. 
Embryologically, the septum between the atri a i made of eptum primum covering the ostium pri mum orfice, and the 
eptum ec undum covering the ostium secundum orfi ce. In 70% of the populatio n, these epta fu e. A patent fo ramen 
ovale ex i ts if the space is covered but the epta are not fu ed . An AS D exists when an open communication exists 
between atri a. A large AS D can cau e ex tra blood to accumulate in the right atrium and ri ght ventric le . Eventuall y, the 
hunted fl ow causes right ide di latati on, main pulmonary artery enlargement, and increase in pulmonary vasculature . 
Most ASD are asymptomatic in infancy and pre ent upon routi ne physical exami nati on. T he time it takes for 
symptom uch a heart failure, genera lized edema, exerc i e in to lerance or dyspnea is inver e ly re lated to the ize of 
the ASD. O n phy ical exami nation, the most common fi ndi ngs are a precord ia l bul ge, abnormal murmur , and 
ex traneou heart sounds. The most u e fultest in the identi fi ca tion and quanti fi cation o f the AS D i an echocardiogram 
(tran thorac ic or tran esophageal, with or without Doppler); however, other in ve ti gati on including ECG and chest 
radiography may be uti li zed. Mechanical c losure i ind icated fo r pati ent that develop symptoms or have a large 
degree of le ft-to-right hun t. Hi tori ca ll y, surgical c losure ha been the mainstream treatme nt, but recently 
percutaneou device have come to the fore front in the repair of ostium secundum ASDs because of the ir excellent 
outcome and decrea ed perioperati ve morbid ity. T he transcatheter approach ha all owed e lderly patient and tho e 
wi th co-morbidities to undergo closure of their ASDs and thri ve afterward . 
Case 
A 19 year old tudent presented with an 
incidentally noted irregular heart beat. Pati ent 
worked out regularly, but hi s aerobic endurance 
wa not that great. He was not a smoker. He had 
no family hi tory of congenital heart di sease. He 
did not take any medications, and had no 
allergies. He had no problems with palpitations, 
light-headedne s, or yncope. He had no medical 
hi story. He weighed 76 kg. Hi blood pressure 
was 110170 mmHg. Hi s heart rale wa 62 beats 
per minute and regular. His second heart ound 
was widely split and fi xed. His murmur was 
described as a midsy tolic pulmonary ejection 
murmur. 
Che t x-ray revealed cardiomegaly due to 
ri ght ventric le enlargement. Echocardiography 
revealed that hi s ri ght atrium and right ventric le 
were moderately dil ated. Hi s ri ght ventricle had 
mildly reduced systo lic function, and color flow 
Doppler sugge ted left-to- ri ght shunting. 
Transesophageal ECG found a dilated ri ght 
atrium and right ventricle, moderate right 
ventricle global hypokinesis, and a 1 em o tium 
secundum atri al septal defect with left-to-ri ght 
shunting. 
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Patient underwent a percutaneou device closure. 
Arrangements were made for follow-up in 2 
months. 
Introduction 
Atrial eptal defects (ASDs) are the second most 
common congenital lesion in adults. A patent 
fo ramen ovale (PFO) exi ts in 30-40% of the 
normal adult population.' In an ASD, a defect in 
the in teratrial eptum of the heart allow mixing 
of the blood in the right and left sides of the 
heart. The ex tent of hemodynamic and clinical 
signi ficance depends on the ex tent of shunting. 
Embryology: The mother's placenta provides 
ox ygen for the foetus, o blood can bypa s the 
lungs.2 In earl y weeks of ge tation, an orfice, 
o tium primum, exi ts between the atri a. 
Beginning in the 5th week, the septum primum 
be~in s clos ing th_e orfice. Within thi s septum, an 
orf tce called ostium secundum fo rms, which in 
tum becomes clo ed by the eptum ecundum. 
The _septum ecundum does not complete ly seal, 
leavmg the f~ramen ovale. The septum primum 
forms a flexible fl op on the left side of the 
foramen ovale. However, since the right atri al 
pressure i higher than the left side, the flexible 
flap is pushed aside holding the foramen ovale 
open. At birth, expansion of the lungs and 
increase in systemic vasculature resistance 
reverses the atrial pressure gradient; the flap is 
held down and the interatrial hunt ceases. In 
approximately 70% of the population, the septa 
fuse after birth. A "probe patent" or "patent" 
foramen ovale (PFO) exists if the space is 
covered but the septa are not fused. A reversal of 
the interatrial pressure gradient or an intercardiac 
catheter can open the PFO. An ASD exists when 
an open communication exi ts between the atria. 
Pathophysiology: Many types of ASD exist, but 
the pathophysiology is very similar? Normally, 
the left side of the heart has a higher pressure 
than the right side. A large ASD can cau e extra 
blood to accumulate in the right atrium and right 
ventricle. Pulmonary to systemic flow ratio can 
be as high as 8:1, while some patients can have a 
5:1 ratio but be asymptomatic. Eventually, the 
shunted flow causes right size dilatation , main 
pulmonary artery dilation, and increase in 
pulmonary vasculature. Untreated, the inc rea es 
the size of the right ide of the heart can lead to 
heart failure. Any increase in the pressure in the 
left ventricle, such as by hypertension and 
coronary artery disease, worsens the left-to-right 
shunt. Overload of the right side of the heart, in 
tum, overloads the pulmonary vasculature, which 
leads to pulmonary hypertension. The pulmonary 
hypertension further overloads the right 
ventricle, called afterload, and results in the right 
ventricle to generate higher pressures to 
overcome the pulmonary hypertension. 
Potentially, the right ventricle fails or the 
pressure in the right side of the heart becomes 
higher than the left side. As the normal pressure 
differential between the right and left ides of the 
heart decreases, the hunting decreases. 
Eisenmenger' s syndrome describes the situation 
where severe fixed pulmonary hypertension 
caused by the shunt leads to elimination of the 
left to right shunt and bi-directional or right to 
left shunting leading to arterial desaturation and 
cyanOSIS. 
Types of ASDs: Many types of ASDs exist? 
Primum ASDs are typically associated with 
ventricular septal defects and/or A V valve 
malformations. Poor growth of the secundum 
eptum or exce sive absorption of the primum 
septum is called secundum type ASD. Thi s type 
accounts for 70% of all ASDs, and i more 
common in female . It can be as ociated with 
other ASDs. Some patient have a family history 
of this defect. An abnormality in the insertion of 
the superior or inferior vena cava can form an 
interatrial communication outside the fo sa 
ovalis. This defect is called sinus venosu ASD. 
When a part of the wall between the coronary 
sinus and left atrium is absent, the defect is 
called coronary inu ASD. A PFO is not a real 
ASD. It can be detected in 25 to 40% of normal 
adult hearts. 3 PFO may be a famili al trait. 
Management 
History and Physical Examination 
The vast majority of small ASDs are 
asymptomatic in infancy and childhood, and they 
are found secondary to hearing an incidental 
murmur upon auscultation of the chest. The 
minority of newborns with small ASDs may 
present with mild cyanosis with right to left 
shunting across the ASD.4 Typically small ASDs 
are not associated with a significant shunt and o 
may not be associated with a mUimur or any 
abnormal findings . Infants and children with 
larger ASDs may pre ent with hea11 failure , 
failure to thrive, or recurrent respiratory tract 
infections.5 Patients with moderately ized 
ASD , if not corrected, will develop symptoms 
such as heart failure , hepatomegaly, generalized 
edema, atrial atTthymias, exerci e intolerance, or 
dyspnea later in life (usually before age 40) as 
the degree of left to right hunting increa es with 
age.6 
There are numerous physical findings 
associated with ASD . Children with an ASD 
may be small for their age, even in the absence 
of complications uch as heart failure . Upon 
palpation of the precordium there may be a 
precordial bulge, a right ventricular heave, or a 
palpable pulmonary artery at the second left 
interspace. During ausculatation of the heart 
commonly a widely spaced second left hear~ 
sound is present hypothesized to stem from the 
increase in pulmonary arterial flow and delayed 
closure of the pulmonic valve.7 This, however, is 
u ually absent in newborn because of a minimal 
left to right shunt. If the ASD is associated with 
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pulmonary hypertension the pulmonary 
component of the second heart sound i louder 
than u ual. The u ually split fir t heart sound 
mi ght be even more pronounced in patients with 
ASDs because of increa ed blood flow needed to 
occur across the valve. 
A variety of murmur may be associated 
with ASD primaril y or econdary to pulmonary 
hyperten ion.7 It is important to realize that the 
blood flow aero s the ASD contains in ufficient 
turbulence to be au cultated. The primary 
murmur incl ude: a mid y tolic pulmonary 
ejection mu rmur becau e of increa ed fl ow 
thorough the pulmonic valve, a mid diastolic 
mu rmur econdary to increased flow across the 
tricu pid valve, a diasto lic murmur consi tent 
wi th pulmonary regurgitation becau ·e of 
pulmonary trunk dilatation, and a y tolic 
ejection murmur be t heard over the lung 
con i tent with increa ed flow th rough the 
smaller pulmonary arteries. Additionall y, with 
pulmonary hypertension patient with ASDs may 
have additional murmur and ex traneous heart 
ounds. 
Other Investigations: In the evaluation of a 
patient with an ASD the most utilized te t are 
the echocardiogram, the electrocardiograph , and 
the chest x-ray. Echocardiograph y is the mo t 
useful te t fo r the diagnosis of ASD. 
Tran thorac ic echocardiography is u ually 
diagno tic; however, transe ophageal 
echocardiograph y can prov ide additional 
information regarding the ize of the defect and 
the other a sociated congenital anomalie . The 
vo lume of blood shunted, the shunt ratios, a 
we ll as pulmonary artery pressure can be 
mea ured with Doppler fl ow echocardiograph y. 
Treatment: The two main indicati ons for surgical 
or percutaneou clo ure of the ASD are the 
development of symptom. or a large left to right 
shunt.4·8 The American Heart A ociation 
recommends closure when the Qp/Qs i greater 
than 1.5:19, while the Canadi an Cardiac Soc iety 
recommends closure when the Qp/Q is greater 
than 2:1 , or greater than 1.5:1 in addition to 
. I l h . 10 rever tb e pu monary yperten ton. 
The traditional surgery performed for 
ASD repairs ha been a medi an sternotomy with 
Pericardia! or Dacron patche , although a ri ght 
anterolateral ubmammary subpectoral approach 
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may be preferred by women for cosmetic 
rea on . 11 •12 There has been an increased use of 
minimally invasive urgery recently, as ~n 
alternative to surgery or percutaneou repa1r. 
Intraoperative tran esophageal echocardiography 
may be u ed to ensure proper closure of the 
defect. Po toperatively, beta blockers and 
anticoagulation reduce the ri k of atrial 
fibrill ation and troke respectively. The 
perioperative mortality of such procedures 
h Om 13·14·15·16 Over the long term, approac e -;o. 
patients still have quite succe sful outcomes, 
e peciall y with ongoing medical therapy, with 
minor differences in survival compared to the 
population, and minimal ri k of needing 
addi tional surgery. Minimally mva 1ve 
approache may reduce the perioperative 
morbidity and decrea ed hospital tay. Dr. K. 
Finnie add that clo ure of the ASD does not 
reduce the incidence of recurrent atrial 
arrh ythmia such a atri al fibrill ation. (Personal 
communication, 2008) 
The FDA ha approved two percutaneous 
devices, Amplatzer Septal Occluder and the 
CardioSEAL eptal Occlu ion Sy tern that may 
be u ed a an alternati ve to treatment. 17 The 
benefit of a transcatheter clo ure are that the 
patient avoid cardiopulmonary bypa , 
thoracotomy, and atriotomy. The outcomes are 
excellent and the tran catheter closure i largely 
replac ing surgical clo ure in orne center for the 
management of appropri ate ASDs. Additionally 
the perioperati ve morbidity, rate of 
complications, and ho pita! tay may be reduced. 
The percutanou method of ASD clo ure will 
become the more preferred method of clo ure, 
e pecially in elderl y patient or tho e with 
ignificant comorbiditie .18•19 Thi nonoperative 
device clo ure only can be used in patient with 
o tium ecundum ASD (about 50-70 o of all 
A~Ds) an~ i not u ed in patients with o tium 
pnmum, mus veno u , or coronary sinu atrial 
eptal defect . The ASD must al o be mall or 
moderately sized, ideally under 20 mm. Dr. K. 
Finnie adds that defects up to 39 mm can now be 
repaired.(Per onal communication, 2008). 
Conclusion 
Atrial septal defect (ASD ) are abnorm 1 
. . a 
commumcatJOns between the left and ri ~:> ht atri a 
allowing mixing of the blood between these two 
compartments. ASDs are the second most 
common congenital lesion in adult . 
Transcatheter closure of ASDs with the 
Amplatzer Septal Occluder and the CardioSEAL 
Septal Occlusion System are streamlining the 
way ASDs are managed. Decreased hospital 
stay, decreased morbidity, and outcomes on par 
or better than with surgery are popularizing the 
minimally invasive procedure for the repair of 
pecific types of ASDs. 
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Zebra Files 
Commotio cordis: an important cause of sudden cardiac death in young athletes 
Ashley Brown, Medicine 2011, ]erma Ashkanase, Medicine 2011, and Tiffany Kwok, Medicine 2010 
Reviewed by Dr. Andrew Krahn 
Although a rare occurrence, commoti o cordis is the second most common cau e of sudden cardiac death in young, 
hea lthy athlete . A slow-moving projec tile (o ften a baseba ll or orne other sport eq uipment) trikes the compliant 
precordium of an affected patient immediately be fore the T wave of the cardiac cycle, causing a premature ventricular 
con traction that induce vemricular fibri ll ation and cardiac arre t. Resuscita tion attempts are often unsucce sful and 
urviva l rate are onl y 15%. Thi review outlines the pathophy io logy and epidemiology associated with commolio 
cordis, and addres es strategies that may help prevent thi s life- threatening occurrence. 
Introduction 
Commotio cordi (CC), also termed "cardiac 
concussion", i a rare but devastating event 
characterized by a eemingly innocuous blow to 
the chest followed by sudden death. 170 ca e 
have been reported in the U.S. Commotio Cordi 
Registry (USCCR) since 1996, almost all of 
whom are young male athlete with no prior 
history of heart abnormalities or dy function. 1·2 
Although it is relatively rare, the eriousness of 
CC warrants investigation into it 
pathophys iology and ubseq uent indication for 
treatment and prevention. 
Case Report 
The patient described by Maron et. al. (2005) 
illustrates many key features present in pati ent 
affected by CC. A 22-year-o ld male who was 
not wearing any protective chest gear was struck 
directly over the precordium by a lacrosse ball. 
He was extremely athletic, had no prev iou Iy 
reported health problems, and weighed 185 lb . 
After being struck, he stumbled two teps and 
fe ll to the ground . A trainer immedi ately ran 
onto the fie ld, determined that a pu lse wa. absent, 
and initi ated cardiopulmonary resu. citation 
(CPR ). A sports med icine physician quickly 
entered the scene with an automated ex ternal 
defibrillator (AED) which detected ventricular 
fibrillation (VF). T he AED deli vered an 
appropriate defibrillation hock of 2001 within 2 
minutes of the athlete's collap e. Thi s 
successfully terminated the VF and advised no 
further shocks, however the man's pulse did not 
return , and CPR was continued by bystander 
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and 5 minutes later by paramedics. The man was 
later pronounced dead in the emergency 
department, approximately 1 hour after collapse. 
A che t x-ray revealed no rib fracture or other 
injurie , and an echocardiogram revealed no 
tructural abnormalitie of the heart. 3 
A in the preceding case, most ca es of 
CC in volve a young male being truck in the 
chest during an athletic event, immediately 
initiating VF. Resuscitation i un uccessful m 
the vast majority of case .4 
A case of commoti o cordis wa een m 
London over 10 years ago. Attending phy ician 
Dr. Andrew Krahn recount , "a young healthy 
trucker, father of 2, [was] tightening his load 
with a cheater bar (bi g teel ratchet like bar for 
the strap winch on a tran port truck)... at 
Wellington and the 401. [He uffered a] minor 
blow to the che t [with a] long delay to the 
ambulance." Unfortunately, thi man ultimately 
suffered the arne fate as many commotio cordi 
pati ent and di ed before the ambulance reached 
him. 5 
Pathophysiology 
The pathophysiology of CC is not entire ly 
understood, although Madi as et al. (2006) have 
devised a possible model to explain it 
occurrence. It ha been widely ob erved that key 
factors mu st align in order to cause CC: a 
suffic ient but not exce sive force mu t strike the 
precordium of a relatively compliant che t wall 
just prior to the peak of the T-wave of the 
d . l 1,2.6 ( p· 
car tac eye e ee tgure 1). The force 
striking the compliant che t wall causes a rapid 
increa e in pressure within the left ventricle. 
This tretches the myocardium and activate 
mechano-sensitive ion channel , re ulting in a 
rapid influx of potassium ions and consequently 
a premature depolarization of the myocardium. 
This alone would cause depolarization of a 
ingle beat, but would not be sufficient to cause a 
u tained arrhythmia. However, within a period 
a few milliseconds (15-30ms) before the peak of 
the T-wave, some of the myocyte of the left 
ventricle can be depolarized, while others are 
till refractory and are therefore unable to be 
depolarized. Depolarization of only a portion of 
the left ventricular myocardium results in non-
imultaneous excitation, and thus fibrillation, 
providing a 15ms window of vulnerability within 
the cardiac cycle. 7 
When one is struck directly over the heart, 
the force i transmitted significantly within the 
chest cavity due to mechanical compliance of 
their che t wall.7 If the impact is at exactly the 
rioht time within the cardiac cycle, non-uniform b 
depolarization of the myocardium occurs, 
re ulting in sustained VF and consequently 
sudden death. It i important to note that 
structural damage to the heart and urrounding 
ti sues is not present in cases of CC due to the 
low velocity of impact8; the pressure wave that is 
transmitted to the left ventricle is the basis of the 
pathology. 
CC may occur in any healthy heart.9 
Athletes are more commonly affected because 
they are at greater risk than the average per on of 
sustaining a blow to the chest wall. Young 
people are more commonly affected due to 
increased compliance of their chest wall, 
transmitting the force to the left ventricle more 
easily than adults. Other than these two indirect 
risk factors, CC requires no predisposing 
features. It can theoretically happen to anyone, 
but it is rare because very specific factors must 
align within an extremely small window of 
opportunity. 
Population at Risk . 
The specific factors that coalesce to tngger CC 
place a fairly narrow demographic at ri sk: 
commonly, young male athletes appear to be the 
most susceptible. Indeed, an analysis of 128 
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Figure I . The projectile must strike the precordium 
immediate ly before the T -wave of the cardiac cycle 
!0 (denoted by the arrow) . 
ca e in the USCCR performed by Maron et al. 
(1999) reported that 62% of the events occurred 
in male athletes of median age 14 years during 
sporting competitions. This finding may be due 
in part to sport ' increased ri k of projectiles, 
especially those that are rigid and/or possess a 
den e core such as baseballs and hockey puck , 
hitting one's chest as well as the increased chest 
wall compliance of young athlete described 
above.9 
It is impottant to note that CC can occur 
in non-athletes a well. The USCCR has 
recorded cases in which CC wa induced 
fo llowing chest contact during uch seemingly 
harmless event a horse-play, being struck with 
a snow aucer, and a family pet colliding with a 
ch ild 's chest. 8 While these instances are thou ght 
to be uncommon , they emphasize the point that 
CC can affect almost anyone if all the etiological 
factors are present. 
Strategies for Prevention 
Though cases of CC are considered to be rare 
overall, there has been an increased incidence of 
reports over the past two decades as recorded by 
the USCCR.8 Survival rates are dismal at 
approximately 15%. In athlete this condition 
has become the second mo t common cause of 
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in tant death. 8' 11 Since several factors are 
involved in the etiology of CC, everal measures 
may be taken to reduce the incidence of thi s 
tragic occurrence. Both emergency medical 
techniques and porting apparatus must be 
examined and improved upon to reduce the ri ks 
of deleterio us effect for athletes. M edical 
profe ionals pre ent during sporting event 
should not onl y be well trained in 
cardiopul monary re u citation and defibrillation 
technique, bu t should al o be educated regarding 
the necessity of quick re pon e when CC is 
u pected. It is thought that as i tance within 3 
minu te or le of collapse may improve the 
outcome fo r some pati ents although it i not a 
guarantee of succe s, as ev idenced by the athlete 
in theca e tudy. 
Methods of altering porting equipment 
and protecti ve gear to reduce the ri k of CC fo r 
athlete have been uggested, most prominently 
fo r baseball and port requmng chest 
protectors.8 The implementation of ofter 
ba eballs was proposed, but met with opposition 
fo llow ing tri al that demonstrated alte red bounce 
and velocity. Ba eball of an intermedi ate 
den ity have been developed and are cun·entl y 
being evaluated as a compro mi e between afety 
and the integrity of the game. Che t protectors 
have fall en under scrutin y for both their 
compo ition and the ir fun ctional capac ity. In a 
tud y conducted by Doerer et al. (2007) 
examining chest protectors, 38% o f the affli cted 
athletes were wearing approved protecti ve chest 
padding. It ha thus been suggested th at the 
dens ity and its distribution within the protecti ve 
gear be altered to prov ide additional defense.8 It 
1 also relevant to note that of the athlete. 
wearing ches t protectors, 25 o f 32 experienced 
di pl acement of the ches t protector during the 
cour e o f game play.12 A more effective mean 
of keeping the protecti ve gear over the cardi ac 
silho uette ho uld be dev ised. 
Conclusion 
Commotio cordi s, though rare, i a particularly 
deva tating cause of fa tality that predo minantly 
affect healthy yo ung male athlete . It is cau ed 
by a projectil e striking one's compli ant 
precordium moments before the T wave and 
causes ventri cular fibrill ation that may not 
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re pond to re uscitation . The ri sk of phy ical 
and projectile contact inherent to sporting 
competition enhance the likelihood of 
usceptibility in athletes, but non-athletes may 
also be affected if the etiological factors 
converge. Although CC is considered to be a 
relatively uncommon event, its ris ing incidence 
and tragic consequence nece sitate increased 
awareness and preventive effort on several 
levels . 
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Feature Article 
An overview of using cost-effective measures in preventing cardiovascular disease 
Dinesh Bhayana, Medicine 2010 
Reviewed by Dr. John Feightner 
Cardiovascular di ea e carries a worldwide economic burden higher than any other chronic disea e. The aging 
population of developed nations have played a major ro le in the rapidl y increa ing the cost of deli vering healthcare. 
In order to continue providing public healthcare to all citizen , the Canadian government mu t look beyond increas ing 
pending and focu on the appropriate allocation of available resources. Cost-ef fec ti ve methods o f healthcare deli very 
should be con idered as a mean o f reducing the growing economic burden o f cardiova cular disea e and other chronic 
diseases. Prevention of cardiovascu lar di ease has hown promise as a co. t-e ffecti ve tool in the ex isting literature. 
Further investigation is required to develop a clear picture o f the role that prevention will pl ay in reducing co ts and 
delivering high quality healthcare to Canadians. However, the exi sting evidence should compel current and future 
phy ician to appreciate the increasingly important role that cost-effective analy es will play in shaping the future o f 
our healthcare system. 
Introduction 
Healthcare spending by the federal and 
provincial governments in Canada has come 
under crutiny in recent years. Public discontent 
and nation-wide anxiety have surfaced a the 
co t of delivering healthcare climbs higher. 
Once a solely economic and political issue dealt 
with by policy makers in Ottawa, the topic of 
healthcare pending is now seen in newspaper 
and magazines in homes acros the nation. It has 
long been recognized that among the reforms 
needed to revive public support of Canadian 
healthcare, control of spending must be a 
priority. To this end, health policy makers 
should systematically addres each determinant 
of government spending that can be manipulated. 
The three factors mo t influential in determining 
healthcare pending in Canada are provincial 
revenue, federal transfer , and the percentage of 
the population over the age of 65. 1 While 
provincial revenue and federal transfers can be 
controlled politically by manipulating fiscal 
policy, the aging population is of concern to the 
medical community. The mechanism by which 
the aging population exerts its effects on 
healthcare in developed nations, Canada 
included, is the increased economic burden of 
chronic disease? Thus, it is of utmost importance 
that medical practitioners understand the nature 
of chronic diseases and ubsequently apply 
government resources in a cost-effective manner. 
In 2001 , the two leading causes of death 
and disability in developed nation were of 
cardiovascular origin.3 Ischemic heart di ea e 
and cerebrovascular di ease ranked fir t and 
second among t a variety of chronic conditions 
that carry a large economic burden. The most 
recent report by the Public Health Agency of 
Canada estimated the economic burden of 
cardiovascular disease (CVD) in Canada to be 
over $18 billion in 1998, an increa e of nearly 
12% since 1986.4 This escalating cost to 
healthcare and society includes direct cost from 
hospitals , physicians, procedures, and 
medications, as well as indirect costs from 
disability and premature mortality. 
Cardiovascular disease is a pnme 
example of the pre sure that chronic di ease 
places on healthcare spending. Patients may 
require immediate high-quality radiographic 
imaging, procedural intervention , and orne 
length of hospital stay. Furthennore, CVD 
patients often require chronic maintenance by a 
multi-drug regimen , routine follow-up including 
blood work, and an array of behavioural 
interventions aimed at reducing the ri k of 
recurrence. It has been established that the ri k 
factors implicated in CVD are modifiable prior 
to the on et of disease and can reduce the ri sk of 
~ first . eve
5
nt and the need for costly 
~ntervent~ons. Thus, prevention of CVD by 
mtervent10ns
6 
of proven efficacy, a outlined in 
the literature , should decrease the overall burden 
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of thi costl y di ease. This logic ha been 
pro moted by health professionals for some time 
bu t ha onl y recently begun to manife tin policy 
changes. Thi likely due to the fac t that 
prevention strategies are, unlike curati ve 
trategies, characterized by immediate costs and 
delayed benefits. 7 Using data fro m cost-effecti ve 
analyse to develop practice guideline i 
currently a complex undertaking due to inherent 
li mitation in the publi hed li teratu re. The wide 
variation between studie in the in tervention 
cho en, methodology and interpretation ha 
made it d iffic ult to implement their 
recommendations. However, by recognizing that 
economically sound in tervention exist, current 
medical tudents and practi tioners can face 
govern ment pre sure to provide cost-effecti ve 
healthcare with innovati ve approache . 
Overview of the evidence for cost-effective 
prevention 
Primary prevention i characteri zed by measures 
that decrea e the likelihood of a fir t occurrence 
of the di ease th rough health pro motion, 
c reening for ri k fac tors, and ri sk fac tor 
modification.7 A particular et of guideline for 
primary preventi on of CYD6 li ts ri k facto rs 
that can be modified in several ways including 
health pro motion, poli tical acti on, 
pharmaceutical intervention, and behavioural 
modi fication. Hyperlipidemia, hyperten ion, and 
cigarette smoking are modifi able ri sk factors 
with a variety of interventions that are cost-
effecti ve if used appropriate ly. The most cost-
effecti ve route of ac ti on is often attained by 
choo ing in tervention targeted at the ri k profile 
of the ind ividual patient in question. Therefore, 
knowledge of co t-effecti veness i imperati ve to 
tho e developing and implementing appropriate 
prevention guidelines. 
The reduction of serum cholesterol levels 
through primary prevention has been shown to 
reduce the ri sk of an adverse cardiovascul ar 
event. 6 HMG-CoA reductase inhibitors (s tatin ) 
and dietary modi fication are effecti ve tool in 
lowering levels of erum low density lipoprotein 
(LDL) in many populations, but their roles as a 
cost-effective means of preventing CVD vari e 
by ri sk subgroup. In a review of cost-effective 
analyses, authors fo und that tatin therapy is 
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nearly 4 times more cost-effective in the primary 
prevention of CVD in men with elevated erum 
LDL and three other ri k factors than in men 
with serum LDL elevated to the same degree and 
no other risk factor present. Statin therapy in 
both these popul ations of men was still 
considered cost-effecti ve, while initiating 
therapy in younger women with erum LDL 
elevated to the ame degree and no ri sk factor 
was not considered cost-effective.8 The initiation 
of a low-fat, low-chole terol diet through 
physician counseling and mass-media health 
promotion has al o been shown to be co t-
effecti ve in certain risk subgroup . In an 
evaJuation of guideline fo r LDL target , authors 
determined that employing dietary modification 
as a primary prevention mea ure i co t-effective 
fo r nearl y all men regardless of ri sk subgroup 
and women over the age of 55.9 
Hyperten ion can harply increa e the 
ri k of C VD when multiple ri k factors are 
pre ent, hence the need for aggressive 
therapeutic target .6 In a large cost-effective 
analy i tudy of a number of diffe rent risk 
fac tor intervention , two hyperten ion therapies 
howed promi ing re ult . While deemed 
generally co t-effecti ve in multiple ubgroup of 
on particular tudy, initiation of a B-blocker and 
diuretic regimen wa fo und to be con iderabl y 
more co t-effecti ve in pati ents with a y tolic 
blood pre ure of greater than 160mmHg when 
compared to those with a ystolic blood pre ure 
of 140 to 159mmHg. Also, the introduction of 
population-wide legi lation to decrea the alt 
content in proces ed food proved to be extremely 
co t-effecti ve in reduc ing CYD-induced 
di abili ty re lated to hyperten ion.10 
Although the adver e health effects of 
cigarette smoking are le s specific to C YD than 
hyperlipidemi a and hypertension, moking 
ce .. ati ~n l s of high ptiority in primary 
prev~n.twn . In one tudy, moking ce ation by 
physic ian counseling wa fo und to be a more 
cost-effecti ve approach to primary prevention of 
CYD than therapy fo r hyperlipidemi a o r h . 8 yperte.n 10 11 . ~he ma s medi a approach of 
promotmg moking ce . ation wa fo und to be 
less cost-effecti ve than phy ician coun ' eli no to 
those pati ents with more than one oth r ~i k 
factor. Al o, moking ce sation wa found to be 
le cost-effective than dietary modification m 
the overall prevention of CVD.12 
Discussion 
There exists a strong body of evidence for the 
cost-effectiveness of measures in CVD 
prevention. Despite the difficulties in clinically 
applying co t-effective analyses, the current 
body of literature ha provided a solid basis upon 
which further investigation can build. The 
overview provided here illustrates the 
importance of targeting groups of patient based 
on their risk profile and utilizing appropriate 
primary prevention measures to modify ri sk 
factors . While cost-effective tools for primary 
prevention should be used, each intervention has 
a threshold of risk subgroups outside of which it 
is no longer cost-effective. Thus, the use of a 
single prevention algorithm would result in 
overshooting prevention and wasted resources or 
under hooting prevention and increased disease 
burden. An adaptive and patient-centered 
approach i necessary to pro peri y apply 
preventive measures to the variable population of 
individuals at ri sk for CVD. 
While CVD currently accounts for the 
greatest economic burden to the healthcare 
system, a preventive revolution aimed at 
modifiable risk factors in the Canadian 
population will likely have widespread influence. 
The risk factors for CVD are implicated in a 
wide array of chronic diseases including 
respiratory, endocrine and hepatic conditions, as 
well as a number of malignancies. As the burden 
of these chronic diseases continues to put 
pressure on the healthcare ystem, the need for a 
strong preventive medicine agenda becomes 
increasingly apparent. The role of economics in 
understanding the effective use of prevention 
will continue to grow a challenges in modeling 
and investigation are overcome. Thus far, 
current and future practitioner should be aware 
that research supporting the cost-effectiveness of 
primary prevention in CVD exists and that 
studies in this field may soon move from balance 
sheet to bedside. 
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Feature Article 
Health Canada Ban on Ephedrine - A Post-ban Assessment of Effectiveness 
Is/w inder S. Chattha, Medicine 2011 
Reviewed by Dr. David Masse[ 
Ephedrine i the pharmacologically active alkaloid found in extracts from the Ephedra genu of shrubs nati ve to 
Central A ia. It pharmacologica l propertie have been put to u e in variou weight-lo s products, athletic enhancers, 
deconge tants and bronchodi lators. Due to i t primaril y negati ve cardiovascular effec t , an incomplete ban ha been 
placed by Health Canada on ephedrine u age, which i now restr icted to use solely in nasal deconge ti ves and 
re tri cted to 8mg doses. Ephedri ne bans have been ucce sfu l i n reducing ephedrine ales, however it ha not been 
effecti ve in changing the widespread bel iefs o f co llege tudent or eli mi nating illegal ephedrine u age. The ban also 
doe not take into account the ynergi tic effect of ca f feine and ephedrine. Additional re earch into the ynergistic 
effects of ca ffeine and ephedrine should be conducted in order to address the need o f a full ban in order to protect 
again t cardiova cular compl ications. 
Introduction 
Governmental restnctiO n on the usage of 
pharmacologically ac ti ve ub tance can be 
triggered by newly uncovered scientific 
evidence, increasing public awareness , political 
moti vation , or a combination of these factor 
among others.u Post-re triction data JS 
commonl y lacking in regards to effecti venes of 
po licie , implementation, and regul ation. Thi 
article a esses the po t-re triction literature in 
regards to the 2001 Health Canada re triction on 
the usage of ephedrine to determine the 
effecti veness of the incomplete ban. 
Ephedrine i the pharmacologically 
acti ve alkaloid found in ex tracts from the 
Ephedra genus of hrub nati ve to Central A ia. 
Ephedrine is a sym(1athomimetic amine, which 
exert it affects primaril y th rough interacting 
with a - and ~ -adrenergic receptors which 
mediate sympatheti c responses. It also stimul ate 
the release of endogenou catecholamine and 
inhibit there reuptake from the synapse.3 
Ephedrine' s ac tion on the ·ympatheti c nervous 
sy tern have been put to use in various weight-
lo product , athleti c enhancers, concentration 
aids, deconge tants and bronchodil ators.4 
Several adverse cardi ac event have been 
documented from ephedrine usage: the mo t 
evere including myocardi al infarction, troke, 
and sudden death . 5 In 200 l , after 60 adverse 
events were reported in Canada, Health Canada 
restri cted the sale and dosage limit of ephedrine 
products. Ephedrine is now authori zed for u e 
UW MJ 77(2) 2008 46 
onl y as a na al decongestant and at a maximum 
dose of 8 mg with no more than 32 mg in a 24 hr 
. d 6 peno . 
It i important to a ess the change in 
ephedrine u age and ephedrine-related adver e 
events after the re triction has been put in place 
in order to evaluate the effectivene of uch 
legislation as it is a common form of prevention. 
This article look at the literature concerning 
ephedrine re lated adver e event and 
epidemiological data in order to asses the 
rationale and effecti vene of Health Canada ' s 
incomplete ban on ephedrine products. 
Pharmacological Properties 
Ephedrine' ympathomimetic effec t are 
medi ated th rough interac tions with a - and ~ -
adrenergic receptor . It al o timulate the 
re lea e of endogenous catecholamine from 
neurons through increasing the number of 
ve icle relea ed during each action potential and 
al o delays their reuptake from the synap e It 
affinity to ~ -receptor is greatest for ~1 followed 
by ~2 then ~3 recepto rs.7 Ephedrine produces 
positi ve ionotropic effect and chronotropic 
effects. It i a powerful vasocon trictor and i 
arrythmogenic. 
Ephedrine readily eros e the blood-brain 
banier producin g central nervous y tem effect 
resembling tho e o f amphetamines. Ephedrine 
has an 85% bioavailability, half life of three to 
ix hours, and IS removed through renal 
excretion. 8 
Adverse Effects 
Before ephedrine re triction were put in place in 
the US , The American Association on Poi on 
Control Centers, in 2003, reported that ephedrine 
related adverse events accounted for more than 
one-half of all reported dietary supplement 
related adverse reaction while ephedrine 
product ales accounted for less than 1% of the 
marketplace.9 This disproportion highlights the 
concerns regarding ephedrine usage. 
The mo t common reported adverse event 
a ociated with e~hedrine usage is hypertension 
and tachycardia.' Ephedrine use has al o been 
associated with both i chemic and hemorrhagic 
stroke, cardiac arrhythmias including ventricular 
tachycardia, coronary vasospasm, acute 
myocardial infarction, tachycardia-induced 
cardiomyopathy, and udden death . 11 
Effectiveness of Incomplete Ban 
Ephedrine products have seen increasing use in 
the past two decade for the unapproved 
purposes of weight loss and improved athletic 
performance. Ephedrine increase the rate of 
weight loss by 0.6 kg per month in comparison 
to placebo. When combined with caffeine, the 
rate increased to 1.0 kg per month greater lo 
than with placebo. 12 In the athletic arena, 
ephedrine and caffeine alone do not have 
significant effects on oxygen consumption, 
carbon dioxide production, or time to exhaustion 
in comparison to placebo. However, when taken 
in ~ombination, ephedrine and caffeine have 
shown to produce up to a 20% to 30% increa e 
m athletic performance as seen through 
imr>rovements m run times and trength-
trai)1ing.1 3 
Although Health Canada has limited the 
dopage of ephedrine, when taken in combination 
with caffeine, a low dose can produce effects 
mjmicking those of moderate (30-40 mg) to high 
d~sages (70-80 mg) of ephedrine. 14 This is of 
p,articular importance as ephedrine combined 
y;ith caffeine produces greater weight loss and 
fmproved athletic performance, the primary 
reason for u e among females and males, 
. 1 15 respective y. 
The protective action of the 8 mg per 
dose, 32 mg/day maximum dosage has been 
found to have limited value as The As ociation 
of Food and Drug Officials (AFDO) states that 
serious adver e effects to ephedrine products 
may occur at do age of 24 mg per day. 16 Life-
threatening adverse reactions have been reported 
to occur with doses of 1 to 5 mg. 17 AFDO is also 
concerned that setting a dosage limit may fa lsely 
imply that a safe dose exists. 
Several States in the US have issued a 
complete ban on ephedrine products. This 
legi lation resulted in a significant reduction in 
methamphetamine usage (produced by ephedrine 
through chemical reduction) a well a 
methamphetamine related hospital admissions. 18 
Ephedrine ales through retail outlets have al o 
dropped si nce the ban. 19 In 1997, National 
Collegiate Athletic A sociation (NCAA) issued a 
ban on all ephedri ne containing sub tance . 
Despite these bans, studies have shown an 
increasing trend in ephedrine usage amongst 
college athletes. In 2001 , a study of NCAA 
athletes howed ephedrine usage at 3.9%.20 
Usage has been ri ing since 1991 , and continued 
to rise even after the ban was put into place.21 A 
2006 study by Bents and M ar h (22) showed that 
among members of an NCAA hockey team, 
59.0% reported that the ephedrine ban would 
make them less likely to use the substance, while 
40.3% reported that they would u e banned 
substances to play at hi gher level. 
De pite the restrictions placed on the 
usage of ephedrine, ephedrine products are easily 
obtainable through products sold a nasal 
decongestants or via the internet? 3 Federal 
authoritie are getting involved a ephedri ne can 
be chemically reduced to produce 
methamphetamines. During 2006, the most 
frequently smuggled precursors fro m other 
countries into Canada was ephedri ne. 
Approximate ly 33.8 million tons of imported 
ephedrine is b ing used by manufacturer each 
year to create non-methamphetamine product 
for sale in Canada? 4 
Conclusion 
With the negative cardiovascular effects of 
ephedrine use, there is a clear methodology 
behind the ban of ephedrine substances. 
Although Canadian data do not currently exist, 
US data pre- and post-ban has hown that 
although the legislation has not completely 
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eliminated non-approved usage, it ha decreased 
its overall incidence however not among select 
population such as college athletes. As urvey 
re ults have shown, ephedrine u age most 
commonly begins during high schoo1.25 Further 
reductions in use may be attainable through 
education of the adverse effects bein u 
' 0 
implemented at the high school and college 
levels, targeting those e pecially at risk fo r 
ephedrine usage: athletes and weight conscious 
individuals. 
The cardiovascul ar complications of 
ephedrine use in combination with caffeine, 
requires further scientific research as few tudies 
exist on thi s topic. If a synergi tic effect on 
producing cardiovascular complications is 
repeatedly fo und such as tho e shown by Persky 
et al. (26), the 8 mg per dose guideline hould be 
reconsidered. 
Cardiovascular events are being reported 
at do age lower than 8 mg. The benefits of 
using ephedrine in pharmaceutical products need 
to be weighed against the risks associated with 
its use, both pharmacological and non-
pharmacological, as over the counter 
medications are a source of ephedrine use fo r 
non-approved purposes? 7 
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Feature Article 
Takotsubo Cardiomyopathy 
A Review of Clinical Features, Pathophysiology and Management 
Xiangning Fan. Medicine 2010 
Reviewed by Dr. Patrick Teefy 
Takotsubo cardiomyopathy i a recentl y described and poorl y recognized clinical entity perhap best known for its 
abi lity to mimic both ST-seome nt e levati on myocardial in fa rction (STEMI) and non-ST-segment elevation myocardial 
b . . . 
in farc tion (NSTEM I), especia ll y in po t-menopausal women and fo llowing stressful situations. Becau e of thiS, It IS 
an important considera tion in the d ifferential diagnos is fo r patients presenting with symptoms and signs consistent 
with acute coronary synd rome (ACS). Apical ba llooning of the left ventric le seen on echocardiography or left 
ventricul ogram with preserved motion or hyperki nesis of the ba al segment i the s ignature appearance o f thi 
condition; however, a diagnosis cannot be made until coronary artery d i ea. e is ruled out with angiography. The 
pathophysio logy of thi condition appear to be re lated to tran ient myocardial tunnj ng econdary to high level of 
circulating catecholami nes. T his appears to be via a di fferent mechanism than that seen in response to myocardial 
ischemia, but the exact mechanism remai ns un known. Although Takotsubo cardiomyopathy is thought to comprise 
2% or less of all presentations of ACS, thi i thought to repre ent an underes timate of the true incidence. Increasing 
awareness of the cond ition as well as the trend towards urgent angiography and primary PCI a the favo ured treatme nt 
of STEMI are expec ted to reveal previously undiagnosed or rni diagnosed case . 
Background 
In 1990, Satoh and colleague 1 described a 
unique cardiomyopathy which has ince become 
known as "Takotsubo cardiomyopathy," 
" transient apical ballooning," "stres -induced 
cardiomyopathy," and "broken heart synd ro me." 
Classically, this condition manifests itself as 
acute-on et retrosternal chest pain , shortness of 
breath , and EKG changes consistent with 
transmural anterior wall infarction, most 
commonly ST- egment elevation in the 
appropri ate precordi al lead .2-4 It is seen most 
commonl y, but not exclusively, in po t-
menopau al women who have ex peri enced a 
udden ph ys ical or emoti onal tress, and is 
accompani ed by a characteri sti c appearance of 
the left ventricle on echocardiography or left 
ventriculography and the absence of 
hemodynamically igni ficant coronary artery 
di sease in the distribution of the left anterior 
descending (LAD) artery.5·6 Takotsubo 
cardiomyopath y, therefore, represents a 
diagnosti c diffi culty in that it must be rapidl y 
and accurate ly di stingui shed from anterior 
STEMI in order to fac ilitate correct c linical 
decision-making regarding therapy for the 
patient with ACS. S ince 1990, the clinical 
features of Takotsubo cardiomyopathy have been 
described7, and di agnosti c criteria established by 
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various groups6·8- 10 ; these invariably emphasize 
the tran ient and rever ible nature o f Takot ubo 
cardiomyopathy, and the ab ence of significant 
coronary artery di ease, ruling out ischemic heart 
di ease as a cau e of ventricular dysfun ction . 
Clinical and Investigative Features 
Much of what i known about the clinical 
presentation and course of Takotsubo 
cardiomyopathy derive from publi hed case 
reports. Since its initi al de cription in the 
literature in 1990, Takot ubo cardiomyopathy 
has been reported with increasing frequency both 
in and outside of Japan. There is a mall rise in 
serum troponin and creatine kinase levels with 
imil ar kinetic to that seen in Acs _2A·6 High 
plasma catecholamines are found in a majority of 
patient at presentation; however, their role in 
the pathogenesi remains poorly under tood and 
these are not generally measured unles there is 
concern about pheochromocytoma. It i not 
clear whether eri al measurements are of value 
for clinical deci ion-making. '' -'4 Pati ents with 
Takotsubo cardiomyopathy, because they do not 
have signi ficant coronary artery disease, are 
thought to have a more favourable clinical 
course than their peers pre enting with MI.15 
At initial pre entation, it is o ften difficult 
to differenti ate Takot ubo cardiomyopathy from 
STEMI via electrocardiography, as ST- egment 
elevations in the appropriate precordial leads are 
een in electrocardiograms (EKG ) performed on 
both set of patient .16·17 A the hyper-acute 
phase pas e , the EKG will evolve, often 
revealing deep T wave inversions in the anterior 
lead and QT prolongation. 1 Much attention, 
therefore, ha been devoted to identifying and 
characterizing the sen itivity and specificity of 
EKG pattern which may suggest STEMI over 
Takotsubo cardiomyopathy, or vice versa. 
Ogura and colleagu ugge t that a con tellation 
of EKG findings-namely, absence of reciprocal 
change , absence of abnormal Q wave and a 
ratio of the ST egment elevations in leads V 4-6 
over elevations in Vl-3 > 1-may be highly 
pecific for Takotsubo cardiomyopathy when 
the e exi t together. 19 Inoue and colleague 
confirmed that the ab ence of reciprocal changes 
and abnormal Q waves on EKG may be helpful 
in differentiating between patient pre enting 
with Takot ubo cardiomyopathy and those with 
anterior MI secondary to occlusion of the 
proximal LAD?0 Bybee and colleagues ugge t 
that patients with Takotsubo cardiomyopathy 
typically pre ent with lower ST egment 
elevations than their peer who present with 
bona fide anterior MI secondary to occlu ion of 
the LAD. 15 However, a the 
electrocardiographic differences between 
Takotsubo cardiomyopathy and anterior STEMI 
are subtle and easily missed and the clinical 
features of these two conditions overlap, urgent 
coronary angiography to rule out ignificant 
coronary artery disease and echocardiography or 
left ventriculography to demonstrate the 
characteristic apical ballooning remain necessary 
for diagno i . 
The characteristic appearance upon 
echocardiography or left ventriculography of the 
heart of a patient with Takot ubo 
cardiomyopathy i of dilation of the apex of the 
left ventricle with pre erved_ or ~~fer-contrac~ion 
of the ba e of the left ventncle.- The ventncle 
is said to re emble a Japane e octopu trap, from 
which the name derives. More recently, a 
variant form of Takotsubo cardiomyopathy ha 
been described in which the ventricular dilation 
occurs not at the apex of the left ventricle, but in 
the mid-ventricular segment.20 Takotsubo 
cardiomyopathy involving the right ventricle ha 
also been reported in the literature.21 An 
inverted pattern ha been de cribed m 
as ociation with central nervous y tern injury 
?2.?4 
and pheochromocytoma.- -
Pathophysiology 
In contrast to the clinical course of anterior MI, 
the impairment in left ventricu lar function een 
in Takot ubo cardiomyopathy i transient, and 
typically recovers within 2 months of initial 
pre entation . Though this transient left 
ventricular dysfunction is thought to represent 
myocardial stunning of the affected portion of 
the left ventricle, wi th or without transient 
myocardi al ischemi a, much remain unknown 
about the pathophysiology of Takot ubo 
cardiomyopathy. 
Recent attempt to explain the 
pathophysiology have settled upon high levels of 
circulating catecholamines a the likely 
pathology underlying thi cardio myopathy. One 
explanation i that ystemic release of 
catecholamines following a stressful event 
result is sufficient to tun the myocardium. Due 
to the high concentration of adrenergic receptor 
in the apex of the left ventricle, thi region is 
preferentially susceptible to catecholamine-
induced tunning.2A Circulating catecholami ne 
are hypothesized to produce left ventric ular 
dysfunction via a mechani m different from that 
seen in ischemia12'25 , although Takot ubo 
cardiomyopathy ha been een fo llowi ng 
coronary artery va o pa m26 and tran ient 
catecholamine-mediated vaso pa m may 
contribute.4 Intere tingly, Takot ubo- like 
cardiomyopathy ha been reported with 
pheochromocytoma, thereby lending credence to 
the ugge tion of catecholamine- induced 
d. 1 d f . 2? ') 7 myocar 1a ys unction. -·- More recently , Ako 
and colleague have noted imilarity between 
Takot ubo-like cardiomyopathy and left 
ventricular dy function following acute brain 
injury, thu rai ing the po ibility of a hared 
pathophysiology. 28 
Alternatively, Ibanez has proposed that 
the phenomenon of Takot ubo cardiomyopathy 
can be better explained by occlu ion of the 
proximal or mid-segment of an exceptionally 
long LAD which wrap around the apex of the 
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left ventricle, resul ting in i chemjc myocardial 
dysfunction, fo llowed by pontaneous 
f . 29-3 1 h" h h . . 11 reper us1on ; t 1 ypot ests 1 not as we -
accepted, but may explain how Takot ubo 
cardiomyopathy may develop in patients without 
significantly elevated plasma catecho lamines. 
Impaired microvascular fu nction may al o be 
present and explain the anatomic pattern of 
ventricul ar dy function extendi ng beyond the 
territory of the LAD.32 
A genetic contribu tion to the etiology 
and/or usceptibi lity ha been recentl y 
ugge ted33, but ha yet to be conclu ively 
proven. 
Management 
There hould be a high index of su ptc ion fo r 
this disorder e pecially in o lder fe males 
fo llowing a recent emotional up et or phys ical 
tress. Differentiation fro m ACS can be di fficult. 
If prompt acces to a cardiac catheteri zation 
laboratory i available , it is the preferred 
approach to accurately diagnose thi s di sorder and 
rule out myocardial in fa rction. Understandabl y, 
if a catheteri zation laboratory is not readil y 
available, orne patients may be di agnosed wi th 
STEMI, and, as a re ult, receive thrombolyti c 
therapy. Emergency echocardiography may 
have a ro le in imagi ng the anatomic dy function 
characteris ti c of Takotsubo cardi omyopath y. 
Initi al therapy is u uall y supporti ve in nature4-6, 
and con ist of a pirin , ACE inhibitor , beta 
blocker , and/or calcium channel blocker 34 , 
though the ir use i omewhat empiri . 
Anticoagulation with heparin ( witching t 
Coumadin) is often used given concern about 
development of in tram ural th ro mbus in the 
ball ooned apex. This can be stopped once the 
ventricul ar function normalizes in 1-2 month . 
Complications 
P I d 35-37 . I u monary e ema , m1tra 
regurgitati on38, cardi ac dysrh ythmi as35·39·40 and 
d. . h k 3641 . d car w gentc s oc ' · are recogmze 
complication , espec iall y in elderly pati ents, and 
these life-threatening complications require 
treatment as per u ual protocol. 2'3'42 Addi tiona! 
noted sequelae of Takotsubo cardiomyopath y 
include pericarditi s43, apical thrombus 
formation44•45, cerebrovascul ar acc ident 
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econdary to embolism of an extstmg apical 
47 
thro mbus46 and left ventricular wall rupture. 
The mortality attributed to Takotsubo 
cardiomyopath y i 1 %? Although the observed 
rate of recurrence is low, it is important to note 
that long term fo llow-up of patients with 
Takot ubo cardiomyopathy i limited? 
Summary 
Takot ubo cardiomyopathy is increasingly 
recognized a a cause of acute chest pain and 
dyspnea mimicbng ACS. It is di tingui hed 
fro m anterior MI on the basis of characteristic 
echocardiographic and/or ventriculographic 
findin g , namely, left ventricle wall motion 
abnormalitie , in the absence of critical coronary 
arteri e teno e . The typical wall motion 
abnormality seen is octopu -pot shaped dilation 
o f the apical and midportions of the left ventric le, 
with normal motion or hypercontraction of the 
base of the left ventri cle, although variant fo rm 
have been de cribed. A lthough the preci e 
pathophysiological mechani m which produces 
these changes in the ventric le i unknown, recent 
ugge tion of tran ient myocardial tunning 
secondary to high level of circulating 
catecholamine appear con i tent with clinical 
observation . Overall , pati ent with Takotsubo 
cardiomyopath y hav a favo urable progno i , but 
may experience complication related to 
tran ient left ventricular dy func tion which 
require supportive care. 
References 
I . Satoh H, Tmci hi H. Uchida T. Takot ubo-type 
cardiomyopathy due to multi ve se l pasm. ln : 
Kodama K, HaLe K, Hon M . (eds). Clinica l a pects of 
Myocard ial Injury: From I chemia to Heart Failure. 
Tokyo: Kagakuhy uron, ya o. 1990: 56-64. 
2. Dhar S, Koul D, Subramanian S, Bakhsru M . 
Transient apical ballooning: sheep in w lve ' garb. 
ardiology in Review 2007 ; 15: 150- 153. 
3. I Jansen PR. Takot ubo card iomyopathy: an under-
recognized myocardial yndrome. Eur J tnt M ed 
2007; 18:56 1-565. 
4. Lyon_ AR, Ree PSC. Pra ad S, Poole-Wil on PA, 
Hardmg SE. Stre (~akot ubo) cardiomyopathy- a 
novel pat~op~y JologJcal hypothc i to explain 
catecholammc-mduced acute myocardial tunnin o 
Nat Clin Prac t Cardiova c Med 2008;5:22-29. o· 
5. Desmet WJ, Adriaensse ns BF, Dens JA. Apica l 
ballooning of the left ventricle: first seric in white 
patient . Heart 2003;89: 1027- l 03 I. 
6. Bybee KA, Kara T , Pra ad A, Lerma n A, Bar nes 
GW , Wright RS , Rihal CS. Syste mati c review: 
tran ie nt le ft ventric ular apical ba llooning: a syndrome 
that rrurrucs ST- egment elevation myocardial 
infarction . Ann Intern Med 2004 ; 141:858-865. 
7. Kuri u S, Sato H, Kawagoe T , I hihara M, Shimatani 
Y, Ni hioka K, Kono Y, Umemura T , Naka mura S. 
Tako-tsubo- like left ventricul ar dysfunc ti on wi th ST-
segme nt e leva tio n: a novel cardiac syndrome 
mimicking acute myocardial infarction. Am Heart J 
2002; 143:448-455 . 
8. Abe Y. Kondo M . Apica l ba ll ooning of the left 
ventric le: a di tinct c linical entity? Heart 
2003;89:974-976. 
9. Krantz MJ . Expandi ng diagno ti c criteria fortran ie nt 
left ventri cular apical ballooning. Ann Intern Med 
2004 ;141:889. 
10. Sharkey SW, Lesser JR, Zenovich AG , Maron MS , 
Lindberg J , Longe TF, Maron BJ. Acute and 
reversible cardiomyopathy prov ked by stress in 
women from the United States. Circulati on 
2005;1 11 :472-479. 
11. Ito K, Sugihara H, Katoh S, Azuma A, Nakagawa M , 
Asse sment of Tako tsubo (ampulla) cardiomyopath y 
using 99 mTc-tetrofosnun myocardial SPECT-
comparison with acute coronary syndrome. Ann Nuc l 
Med 2003; 17:115- 122 . 
12. Aka hi YJ , Nakazawa K, Sakakibara M, Miyake F, 
Musha H, Sasaka K. 123-l MIBG myocardia l 
scintigraphy in patie nts with "T akot ubo" 
cardiomyopath y. J Nuc l Med 2004;45:11 2 1-1127. 
13. Kuri u S , Inoue I, Kawagoe T , Masaharu I, Yuji S , 
Suji N, Ma ha hi Y, Naoya M, Takaki H, Hikaru S. 
Time course o f e lec trocardiographic changes in 
patients with tako- tsubo syndrome : comparison with 
acute myocardial infarcti on with mi nima l enzymatic 
release. Circ J 2004 ;68:77-8 1. 
14. Witt te in IS, Thie mann DR, Lima JA, Baughma n KL, 
Schulman SP, Ger te nblith G, Wu KC, Rade JJ , 
Bi valacqua TJ, Champ ion HC. Ne urohumoral 
features of myocardia l s tunning due to sudden 
e motional tres . N Engl J Med 2005 ; 352:539-548. 
15 . Tere fe YG , Niraj A, Pradhan J , Kondur A, Afon o L. 
M yocardial infarction with ang iographicall y norma l 
coronary arteri es in the conte mporary era. Cor Art 
Di 2006; 18:62 1-626. 
16. Inoue M , Shimi zu S , Ino H, Yamaguc hi M, Terai H, 
Fujino N , Sakata K, Funada A, T atami R, I hi se S, 
Kanaya H, M abuchi H. Differentiation between 
pati ents with T akotsubo cardiomyopath y a nd tho e 
with anteri or acute myocardial infarc ti on. Circ J 
2005 ;69:89-94. 
17. Bybee KA, M otie i A, Syed IS, Kara T , Pra ad A, 
Lennon RJ , Murphy JG , Ha mmill SC, Riha l CS , 
Wright RS . Elec trocardi ography cannot re liably 
differentiate transie nt le ft ve ntricular ap ical ballooning 
syndrome from an terior ST-segment e levation 
myocardia l infarction. J E lectrocardio l 
2007;40:38.e 1-38.e6. 
18. Mitsuma W , Kodama M, Ito M, Tanaka K, Yanagawa 
T , Ikarashi N, S ugiura K, Kimura S, Yagihara N, 
Ka himura T , Fuse K, Hira no S, Okura Y, Aizawa Y. 
Serial e lectrocard iograp hic findin g in wo me n with 
Takotsubo cardi omyopath y. Am J Cardi o l 
2007 ;100: 106- 109 . 
19. Ogura R, Hiasa Y, Takahashi T , Yamaguchi K, 
Fuji wara K, Ohara Y, Nada T , Ogata T , Kusunoki K, 
Yuba K, Hosokawa S , Kishi K, Ohtani R. Specific 
findings o f the tandard 12- lead ECG in patie nts with 
'T akotsubo' cardiomyopathy: compari son with the 
findi ngs o f acute anterior myocardi al infarcti on. C irc 
J 2003;67:687-690. 
20. Tamura A, Kawa no Y, Watanabe T , Aso T , Abe Y, 
Yano S, Kadota J . A report of 2 case of transie nt 
mid-ventric ular ballooning. Int J Cardio l 
2007 ; 122 :e LO-e 12. 
2 1. Hag hi D, Athanasiadi A, Papava iliu T , Su e lbeck T , 
Fluec hter S, Mahrho ldt H, Borggrefe M, Sechtem U. 
Right ventri c ul ar in vo lvement in Takot ubo 
cardiomyopathy. Eur Heart J 2006;27:2433-2439. 
22 . Di Va lentino M , Balestra GM, Christ M, Ra ineri I, 
Oertli D, Ze ll weger MJ . In verted Takot ubo 
cardiomyopathy due to pheochromocytoma. Eur 
Heart J 2007 ;In press. 
23. E nnezat PV, Pesenti-Rossi D, Aubert JM , Rache nne V, 
Bauchart JJ , Auffray JL, Logeart D, Cohen-So la! A, 
Asseman P. Transient le ft ventri c ular basa l 
dysfunction without coronary te nos is in acute 
cerebral di sorder : a novel heart syndrome (inverted 
Takotsubo). Echocardiography 2005;22:599-602. 
24. Sanchez- Recalde A, Costero 0 , O li ver JM, Iborra C, 
Rui z E, Sobrino JA . Pheochromocytoma-related 
cardi omyopath y: in verted Takot ubo contracti le 
pattern . Ci rc ulation 2006; 11 3:e738-9. 
25. Yo hida T, Hibino T , Kako N, Murai S, Oguri M , 
Kato K, Yajima K, O hte N, Yokoi K, Kimura G. A 
pathophys io logic study of tako-tsubo cardiomyopath y 
with F- 18 tluorodeoxyglucose pos itron e mission 
topography. Eur Heart J 2007 ;28:2598-2604. 
26. Dote K. Sato H, Tate ishi H, Uchida T , Ishihara M . 
Myocardial stunning due to s imultaneou multi ve se l 
coronary pasms: a review of 5 cases. [Article in 
Japane e] J Cardiol. 199 1;2 1(2):203- 14. 
27. T ake no Y, Eno S , Hondo T , Matsuda K, Zu hi N. 
Pheochromocytoma with reversa l o f tako-tsubo-like 
tra n ie nt left ventric ul ar dy function : a case report. J 
Cardio l 2004 ;43:28 1-287. 
28. Ako J , Sudhir K, Farouque HMO, Honda Y, 
Fitzgerald PJ . Tran ie nt le ft ventric ul ar dy functio n 
under severe stress: brain-heart re la tion hip revisited . 
Am J Med 2006; 11 9: 10- 17. 
29. Ibanez B, Navarro F, Farre J , M arco -Aiberca P , 
Orejas M, Rabago R, Rey M , Romero J , Iniguez A, 
Cordoba M . [Tako-tsubo syndrome associated with a 
long cour e of the le ft a nteri or descending coronar y 
artery along the apical diaphragmatic urface of the 
left ventric le. ] Rev E p Cardio l 2004;57:209-2 16. 
30. Metzl MD, A ltma n EJ , Spevack OM, Dodda ma ni S , 
Travin Ml, Ostfeld RJ . A case of Takotsubo 
UWOMJ 77(2) 2008 53 
cardi omyopathy mimicking an acute coronary 
syndrome. Nat Clin Pract Cardiova c Med 2006;3:53-
56. 
31. Ibanez B, Benezet-Mazueco J, Navarro F, Farre J, 
Diaz-Capio FJ. Mayo Clin Proc 2006;81:732-735 . 
32. Kume T, Akasaka T, Kawamoto T , Yoshitani H, 
Watanabe N, Neish.i Y, Wada N, Yoshida K. 
A sessment of coronary microcirculati on in patient 
wi th Takotsubo- like le ft ventricul ar dys function. Circ 
J 2005;69:934-939. 
33. Pi on L De Vusser P. Mullens W. Apical ballooning 
in re lati ves. Heart 2004 ;90:e67 . 
34. Akashi YJ . The clinical features of Takotsubo 
cardiomyopathy. QJM 2003;96:563. 
35. Tsuch.iha hi K, Ue hima K, Uchida T, Oh-mura N, 
l(jmura K. Owa M, Yoshi yama M, Mi yazaki S, Haze 
K. Ogawa H, Honda T, Hase M, Kai R, Morii I. 
Transient left ventricular apical ballooning without 
coronary artery tenosis: a novel heart yndrome 
mimicki ng acute myocardial infarction. J Am Coli 
Cardiol2001 ;38: 11 - l8. 
36. Connelly KA, Macisaac AL Jelinek VM . Stre , 
myocardial infarction and the ' tako-t ubo' 
phenomenon. Heart 2004;90:e52. 
37. Tsui PT, Cheung KC, Lau CL, Choy CC. A Chjne e 
patient with severe Takotsubo cardiomyopathy. Int J 
Cardiol2007;119:134- l35. 
38. Chandrasegaram MD, Celermajer OS, Wilson MK. 
Apical ballooning yndrome co mplicated by acute 
severe mitral regurgitation with le ft ventricular 
outflow obstructi on--case report. J Cardiothorac 
Surg 2007;2: 14. 
39. Saskai 0 , Nishioka T , Akima T, Tabata H, Okamoto 
Y, Akanuma M, Uehata A, Takase B, Katsushika S, 
UWOMJ 77(2) 2008 54 
lsojima K, OHtomi S, Yoshimoto N. A sociation of 
Takotsubo cardiomyopathy and long QT syndrome. 
Circ J 2006;70: 1220-1222. 
40. Nault MA, Baranchuk A, Simpson CS , Redfearn DP. 
Takotsubo cardiomyopathy : a novel "proarrhythmic" 
disease. Anatol J Cardiol2007;7 Suppl 1: 101-103. 
41 . de Vasconcelos JTP, Martins S, de Sousa JF, Portela 
A. Takotsubo cardiomyopathy : a rare cause of 
cardiogenic sock imulating acute myocardial 
infarction . Arq Bras Cardiol 2005 ;85: 128-130. 
42 . Sakai K, Ochiai H, Katayama N, Nakamura K, 
Arataki K, l(jdo T , Iwamoto H, Nakamura S, 
Nakanjshi T. A seriou clinical cour e of a very 
e lderl y patient with Takotsubo cardiomyopathy. 
Heart and Vessels 2005 ;20:77-8 1. 
43. Maruyama T , Hanaoka T, Nakajima H. Acute 
pericarditi s in the recovery phase of transient left 
ventricular apical balloorung syndrome (Takotsubo 
cardiomyopathy). Int Med 2007;46: 1857- 1860. 
44. Yoshida T, Hibino T, Fujimaki T , Oguri M, Kato K, 
Yajima K, Ohte N, Yokoi K, l(jmura G. Tako-t ubo 
cardi omyopathy complicated by apical thrombu 
formation : a case report. Int J Cardiol 2007:In press. 
45 . Schmidt M, Herholz C, Block M. Apical thrombus in 
tako-t ubo cardiomyopathy. Heart 2007; 93 :1368. 
46. Grabowski A, l(jlian J , Strank C, Cieslinsk G, 
Meyding-Lamade U. Takot ubo cardi omyopathy : a 
rare cau e of card ioembolic troke. Cerebrovasc Dis 
2007 ;24: 146- 148. 
47 . Aka hi YJ , Tej ima T , Sakurada H. Matsuda H, Suzuki 
K, Kawasaki K, Tsuchi ya K. Hashimoto N, Musha H, 
Sakakibara M, Nakazawa K, Miyake F. Le ft 
ventricular rupture assoc iated with Takot ubo 
cardi omyopathy. Mayo Clin Proc 2004;79:82 1-824 . 
Feature Article 
Genetic Basis of Coronary Artery Disease 
Matthew Lanktree, Medicine I PhD 2012 
Reviewed by Dr. Robert A. Hegele 
While fanuly history i a strong ri sk factor for coronary artery di ea. e (CAD), the actual molecular basis has not been 
chara terized in mot ca e. In 2007, four genome-wide a ociation studies (GWAS) reported strong as ociation (up to 
p=l0-22) between a region of chromo orne 9p2 1 and CAD. The high ri k genotype was found in up to 30% of people, 
creating the potential for a clinica l genetic te t to a ist in the prediction of a patient' ri sk for CAD. However, the 
reported effect ize of the association is modest (odds rati o - 1.3) and incorporati on into a clinica l setting may be 
premature. Thi paper reviews the advance in human molecular genetic allowing for the production of GWAS, and a 
re ult of the four GWAS of CAD relea ed in 2007. In addition, these four GW AS are meta-analyzed and the pooled 
ignificance and effec t size e timate are ca lculated. A of yet, there is no explanati n for the basis of the assoc iation of 
this region of chromosome 9 with CAD. The consistency of the as ociation aero populations sugge ts a biologica l 
mechani m i re ponsible. Perhaps the greate t contribution from the assoc iation i yet to come, a further studie 
identify the mechani tic ba is for the lrong assoc iation, possibly lead ing to additional in ights into the progre ion, 
prevention , and treatment of CAD. 
Completion of the sequencing of the human 
h. I 7 genome wa a monumental ac 1evement. ·-
Molecular re earcher now take for granted the 
information provided by the sequence, however 
the clinical application are not immediately 
obvious. A limitation of the Human Genome 
Project wa that it produced only a s ingle 
"reference" equence. But in order to identify 
new disease causing mechanisms and cures for 
di ea e, we need to go beyond the " reference" 
and characterize the differences between our 
genomes, and in turn the effect that these 
differences have. The Human HapMap 
consortium3 and recent genome-wide association 
studies (GW AS) have set out to capture the inter-
individual difference that are associated with 
di sease proce se , including coronary artery 
di sease (CAD). 
Basics of Genetic Variation 
Every human nucleu contains 46 chromo omes 
organized into 23 homologou pair : 22 
autosomes plus a sex chromo orne inherited 
from the mother and 22 autosome plus a ex 
chromosome inherited from the father. 
Chromo orne are made of DNA and can be 
divided into gene , which are area that are 
transcribed into mRNA then translated into 
proteins, and intergenic regions, which can 
contain tran cription regulating elements. Only 
-5% of the genome is thought to be tran lated 
ultimately into protein ; the remainder i ilent. 
Mo t of the genomic sequence ( -99.5% ), 
whether coding or silent, invariant between 
individual . 
The mam form of genomic difference 
between people is the s ingle nucleotide 
polymorphi sm (SNP, pronounced " nip"). A 
SNP is a ingle ba e pair change in the DNA 
sequence that, by convention, occurs in at least 
5% of the population. With the human genome 
equence known, the location of any 
polymorphi sm can be preci ely determined. Each 
SNP i repre ented by two allele , together 
called a genotype, with one allele re iding on 
each homologou chromosome. SNPs are the 
most ba ic and ea ily measured forn1 of genetic 
variation that might lead to inter-individual 
differences at the level of the phenotype. A gene 
can contain zero to many SNP : on average 
SNP occur about 1 in every 300 to 400 base 
pair , and gene range in size from le than a 
thou and to more than two mi ilion ba e pair .-1 
DNA i replicated extremely effectively with 
very few error . Thus, SNP are generally 
inherited from our parents rather than occurring 
pontaneou ly. Occasionally , a de novo meiotic 
mutation increa es in frequency in ucce ive 
generation to become a SNP, e pecially if it 
confer a survival or fitne advantage. Because 
they are inherited , SNPs can give insight into the 
hi tory of the surrounding block of the 
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chromosome. If an unknown sequence variant 
that alters disease risk resides within the same 
block of DNA a a SNP, known a a haplotype 
block, we can indirectly identify the ri k 
equence variant by examining the co egregation 
of the SNP with the disease. In association 
studie , researchers compare the prevalence of 
alleles of SNPs in cases and control to 
potentially identi fy a ri k block. 
Early in the twenty first century a new 
technology called "SNP chip ", also called 
arrays or o ligonucleotide microarrays, were 
introduced. These SNP chips permit 
si multaneous analysi of up to a million SNP 
genotypes aero the genome in a single 
experiment for a single DNA sample. Le s than 
five year ago, u ing older technology a highly 
motivated graduate student might produce 400 
genotypes in a day. Using SNP chips, large 
genetics centres can now perform GW AS to 
measure millions of variants in thousands of 
case and controls in a few days. In 2007, SNP 
chips were combined with the GW AS approach 
to di cover new chromosomal regions that were 
as ociated with a range of common disease 
including rheumatoid arthritis, Crohn 's di ea e, 
type 1 diabete , type 2 diabetes, and CAD. 
Genomics of CAD 
CAD is the leading cause of death among North 
Americans. Smoking ce sation , weight and 
Publication Number Number 
date of cases of 
contro ls 
Helgadotti r et al. 6 June 2007 4587 12767 
McPher on et al. 7 June 2007 3989 18808 
WTCCC~ June 2007 1926 2938 
Samani et a/.9 Aug. 2007 875 1644 
Combined 11 337 36 157 
diabetes management, low-dose aspirin , 
hyperten ion control, and lipid-lowering therapy 
can substantially reduce the ri sk of CAD. Many 
rare single-gene disorders have been discovered 
that substantially increase the ri sk of CAD but 
are only present in a small proportion of the 
population (eg. familial hypercholesterolemia 
due to point mutations found in 1 in 500 people). 
Heritability studie of CAD and myocardial 
infarc tion (MI) indicate that common 
usceptibility gene va1iants (perhaps found in 30-
50% of people) are an important part of CAD 
. k 5 n ' . 
Synthesis of large GWAS in CAD from 2007 
Four GW AS from 2007 , performed in samples 
from several different populations, all howed 
that a region on the hort arm of chromosome 9 
(namely 9p21) was associated with increased 
CAD risk. The fo ur studies reviewed in this 
paper will be referred to as Helgadottir6, 
McPherson7, WTCCC8 and Samani9 for the 
remainder of the paper. The chromosome 9p21 
results from these four GW AS will be meta-
analyzed. 
Study samples: Helgadottir tudied patient from 
Iceland, an isolated population, to ensure genetic 
homogenei ty between case and controls. 
McPherson studied European Caucasian 
participants from the Ottawa Heart Study, 
African American and Cauca ian participants 
Popu lation Genotypi ng Number 
method of SNPs 
examined 
Icelandic Ulumina 305 953 
Hap300 array 
Mi xed Custom an·ay 75 000 
2* 
Great Affymetrix 377 857t 
Brita in 500k array 
Caucasian 
German Affymetrix 272 602t 
Caucas ian 500k array 
Table 1. Studies described in thi s paper. Ab bre viati on - WTC C: Welcome Trust Ca e Contro l Con ortium· 
SNP: Si ng le nuc leotide po lymorphi sm. *initial sa mple of 322 cases and 3 12 contro l , replication o f re ulls p~0 .025 
in 1.658 ca e ~~d 9380 controls, 2 9p2 l SN P performed in re maining . ubject . tSNPs that did not meet Hardy 
Wembcrg equ ll1 bnum, had a rrunor a ll ele freque ncy< l %, <989l SNP ca ll ra te, or were on X chromo orne were 
re moved . 
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from the Athero clerosis Risk in Communitie 
Study, Dani h Cauca ian participants from the 
Coppenhagen City Heart Study, and a multi -
ethnic ample from the Dallas Heart Study. 
Control were carefully selected in order to 
ensure equal representation in case and control 
group . Samani cases and control were collected 
from a genetically homogenou region of 
Bavaria in outhern Germany. WTCCC 
exten ively te ted for difference in background 
allele frequencies due to the ethnicity of study 
subjects. Twelve regions from aero the genome 
were found to be heavily influenced by 
geographic variation and were thus removed 
from the WTCCC and Samani tudie . 
Study subjects: All tudie included male and 
female . The Helgadottir ca es were diagno ed 
with aMI before the age of 70 in males and 75 in 
female . The McPher on ca es underwent 
coronary artery bypass grafting, coronary artery 
angiography, or care for acute MI before the age 
of 60. The WTCCC case had a documented 
history of MI or coronary revascularization 
before their 66th birthday. Finally, the Samani 
cases were diagnosed with a MI prior to the age 
of60. 
Statistics: The WTCCC and Samani studie 
reported odd ratios comparing individual with 
two ri sk alleles verse no ri k alleles and 
individual with one ri sk allele verses no ri k 
alleles (genotype odd ratio). The Helgadottir 
and McPher on studies reported odds ratio by 
comparing the number of the ri k alleles pre ent 
in cases to the number of risk alleles pre ent in 
controls (allelic odds ratio). It is poss ible to 
calculate allelic odds ratio from genotype odd 
ratio (each homozygote contributes two alleles 
and each heterozygote contribute one of each 
allele) but not vice ver a; hence, the current 
meta-analysi u es allelic odd ratio . The four 
GW AS did not assess the exact same SNPs due 
to different genotyping technologies, but all 
ignificantly a ociated SNP were located in the 
same haplotype block (Helgadottir, rs l0757278; 
McPheron, rs l0757274; WTCCC, rs6475606; 
Samani , r 4977574). Meta-analysis wa 
performed u ing the Mantel-Haenszel method, 
which create an estimate of the pooled odd 
ratio as uming a fixed effect model using the 
raw data from the individual studies. Haplotype 
block tructure wa 
International HapMap 
H I . 10 ap ov1ew. 
obtained from 
Consortium3 
the 
VIa 
Synthesis findings: The odd ratio, confidence 
interval and chi- quare p-value found for the 
SNP on chromo orne 9p21 are shown in figure 
1. The Mantel-Haen ze l ummary effect e timate 
aero all four tudie i an odds ratio of 1.30 
(95% C.I. 1.25-1.36). 
Odds Ratio 
(95% Confidence Interval) 
0 0.5 1 1.5 2 
Helgadottir P = lxl0·20 
A vs 6 
McPherson p = 1xlo·22 
Avs B 
WTCCC 
AA vs BB 
p = 4xlo-14 
Samani 
AA vs BB 
p = Sxlo·7 
Combined p = 4xlo-69 
Avs B 
Figure l. Fore t plot of odd ratio obta ined comparing 
9p1 l SNPs with CAD from the four GW AS and the 
combined effect e timate u ing Mantel-Haen ze l meta-
analysis. A vs. B indica tes alle li c odds ratio a nd AA vs. 
BB indicates genotypic odd. ratio. 
Discussion 
Thi meta-analysis of 4 large GWAS empha izes 
the trength , significance, and replicability of the 
association on chromo orne 9p21 with CAD. 
The significance level from the combined 
analysis, p = 4xl0-69 , is a result rarely seen in 
statistical analysi of biological sy tern , and i 
approximately equivalent to the probability of 
flipping a non-loaded coin and obtaining head 
227 time m a row. However, despite the 
overwhelming stati stical relationship, it i 
important to recall the difference between 
tati tical ignificance and clinical significance. 
The level of confidence that a difference exist 
between the allele frequencies in CAD case and 
controls implies little regarding the clinical 
implication of this difference. An odd ratio of 
1.3 i hardly sufficient for a clinician to 
introduce any new ri sk factor test or imaging 
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method into hi /her deci ion making fo r a ingle 
patient. In compari on, smoking confer an 
increased ri k of MI with an odd ratio of 3.0 .11 
Simply taking a family hi tory verbally and 
findin g out that a parent had heart disease under 
age 60 confers a 2-fold increased ri k. 12 It is 
ex tremely di ffi cult to plumb the importance of a 
ri k of an odd ratio of 1.3 deri ved fro m a SNP-
based assay on an indi vidual pati ent. 
So why is the geneti c finding important? 
Perhaps thi di covery will ultimate ly contribute 
to our under tanding of the pathogene i of 
CAD. What explains the incredibl y trong 
tati ticall y ignificant assoc iation o f the 9p2 1 
SNPs with C AD? The 9p2 1 haplotype block i in 
the middle o f a tretch of DNA with no known 
fun ction. The clo e t genes to the reported SNPs 
are: 1) MTAP (meth ylthioadeno ine 
phosphoryla e), which is involved in polyamine 
metaboli m and the alvage of adenine and 
methionine; 2) CDKN2A and CDKN2B (cyc lin-
dependent kina e inhibitor 2A and B), which are 
tumour suppressor genes; 3) and DMRTA 1 
(doublesex and mab-3 related tran cription factor 
like family A 1), which i important in exual 
differentiation. However, these gene are 
approximately 45 ki lobase (kb ), 70 kb and 200 
kb away fro m the strongest SNP ignal 
respecti vely. It is poss ible that vari ants at 9p2 1 
could affect the e gene via regul atory element , 
but this i difficult to determine using current 
technologie . Moreover, it i diffi cult to even 
hypothes ize how the e gene c uld be invo lved 
in CAD ri sk. C learl y, there is much more to 
learn and di scover. 
In conclusion, fo ur GW AS publi shed in 
2007 that enro ll ed large and non-overl apping 
tudy popul ations have identi fied a region o f 
9p2 1 to be trongly associated with CAD ri sk. 
The effect ize is too small for the results to be 
eas ily integrated into clinical deci ion-mak ing 
for a single pati ent, but the trength of the 
association suggests that there mu. t be a shared 
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underl ying biological mechanism, although the 
actual mechanism remains unclear at this time. 
Further tudie to identify the reason for the 
trong as ociation may lead to additional insights 
into the progre sion, prevention, and treatment of 
CAD. 
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Feature Article 
Does being "South Asian" increase the risk of CAD? 
Wajid Sayeed, Medicine 2010 
Reviewed by Dr. Robert Hegele 
Since many disea e aetio logies have a gene ti c contributio n, the u e of e thnic categories (or "geographical ancestries") 
can be a useful way of integrating a range of cultural and geneti c attributes in order to e luc idate the association 
between uch factors and disease usceptibility . "South A ia" is u ua ll y defined a the area encompas ing Pakistan, 
Nepal , Bangladesh, India, and Sri Lanka. Numerous observational tudies have been done howi ng that South Asian , 
both in itu in South Asia and in South Asian diaspora communitie , are at increa ed ri sk for cardi ovasc ular disease, 
especially coronary artery disea e (CAD), a findin g with major implicati ons for c linical practice in countries such a. 
Canada, where South Asian are the third most populou imrrugrant group. While not every South A ian may develop 
CAD-related morbidity, one approach to preventive medic ine is the application of interventions in an entire at-ri k 
population, rather than targeting intervention to individuals on a case-by-case ba is. S uch population-wide 
interventions rrught, however, do more harm than good if their ri sks and costs outweigh the ir bene fits, and if they 
cau e the clinician or the patient to neglect modifiable independent ri k factors with a proven cau ative role in disease 
aetiology. We therefore pre ent a critical look at literature suggesting the use of South Asian ethnic ity as an 
independent ri k factor in the development of CAD. 
Epidemiology of CAD in South Asian 
Populations 
Unfortunately, there are no large multi-centre 
studies performed in regions of South Asia, and 
the national figure available from India are 
based on pooling of studies taken from different 
centres at different time points. More 
importantly, such data are not directly 
comparable with those from South Asian 
diaspora communities, for which disease 
prevalence estimates are sometimes more scarce 
and less reliable than mortality rates. World 
Heath Organization (WHO) data are typically 
expressed as DAL Ys, but this is a flawed 
measure of disease burden, and not nece sarily a 
good indicator of ri k. Mortality from CAD in 
India has been calculated to be 0.85 million in 
men and 0.74 million in women, totaling 1.59 
million deaths in 2000. 1 For an Indian population 
of 1.05 billion in 2000, this translates to a 
mortality rate of 151 CAD death 1100000 
people. Global mortality from ischaemic heart 
disease, which correlate closely with 
symptomatic CAD, stands at 115 
deaths/100,000? Like the DALY, mmtality is 
highly ubject to local socioeconomic conditions, 
and is therefore not a good indicator of risk. 
Similar challenges exist in surveillance of South 
Asian populations outside of South Asia, though 
these are mitigated by smaller overall population 
size. For instance, in Canada, ischaemic heart 
disease mortality is roughly similar between 
South Asian men and European-origin men: 
approximately 320 deaths/100000 per year 
between 1979 and- 1993,3 but is increased for 
South Asian versus European-origin women: 145 
versus 109.9 deaths per year between 1979 and 
1993. The comparison is more valid than at the 
international level, given more uniform social 
conditions within Canada. Furthermore, 
prevalence estimates within Canada between 
ethnic group were made in the Study of Health 
Assessment and Ri sk in Ethnic groups 
(S HARE), which showed a prevalence of 8.6% 
in the South Asian origin cohort compared to 
4.9% in the European origin one.4 Data in UK 
and US cohorts show similar trend 5-6 
Is risk genetic? 
While the epidemiological data may support 
increased cardiovascular disease ri sk in South 
Asians versus other populations, this does not 
necessarily imply that genetic factors in the 
group described as "South Asians" are of 
primary importance. Culture - includin o- diet 
t> ' 
activity and social factor - while "heritable," is 
unlike the genome in that the consequences of 
uwo 77(?)? 
cultural factor m determining ri sk might be 
more amenable to modification through 
education and counseling. Some authors, 
however, assert that the degree to which risk is 
increased among t South Asians is too high to be 
accounted for only by li fes tyle fac tor .7 Thi has 
led to considerable di scu sion of whether or not 
South Asian origin hould be considered an 
independent ri sk factor fo r CVD disease.8 
The attempt to find biochemical marker 
for genetically detem1ined risk i in its in fancy 
and has met mixed results. Some work has been 
done as oc1atmg polymorphisms in 
homocysteine metabolic pathways with carotid 
atherosclero i ,9 but a cau ati ve link has not been 
well-de cribed. Thus far, the only biochemical 
marker with a clear as oc iation with South A ian 
origin that i based in geneti cs, and not the 
environment, i a high pla rna level of 
Lipoprotein (a), which has been con idered as an 
emerging ri k fac tor by the U.S. National 
Cholesterol Education Program (NCEP). 10 Both 
l. . 111 d b . . d ] ? l c mica an as1c sc1ence ata - strong y 
ugge t both that Lp(a) is under geneti c control 
and that ex pression of particular alleles plays a 
causative role in atherosclerosis and the 
aetiology of thrombogenic conditions. 
Thi alone does not necessitate that 
elevated plasma Lp(a), or any other independent 
risk factor a sociated with South Asian origin , is 
primarily to blame fo r the increased prevalence 
and mortality of CAD in South A ians. The 
importance of environment and life tyle over 
geneti cs was hi ghlighted in a study by Bhatn agar 
et al in the Lancet, that howed signi ficant 
differences in cardiova cular di sease ri sk fac tors 
between siblings of South Asian ori gin who 
lived in either West London or Punj ab state. 
While some risk factors, such as Lp(a), were 
similar between the cohort , indicating a geneti c 
component, blood glucose, beta cell function, 
serum apo B, and body mass index (BMI) were 
all appreciably worse in the UK cohort. 13 
Since environment, and therefore 
lifes tyle, obviously contributes to the growth of 
CAD amongst South A ians in Western 
countries, research is required to detennine 
whether or not genetics, environment, or an 
interaction between them fundamentall y ex pl ains 
the increa ed ri sk. Unfo rtunately, to date no 
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study claiming an increase in independent risk 
factor amongst South Asians has properly 
controlled for lifestyle factors - instead indirect 
biochemical or anthropometric surrogates such 
as insulin sensitivity, 14 dyslipidemia,7 or central 
adiposity15 have been u ed to argue that South 
Asians are more susceptible to the effects of a 
sedentary li fes tyle, perhaps by virtue of genetics. 
Cultural attitudes towards diet and exercise are, 
however, heritable or perhaps learned, and could 
re ult in increased expo ure of South Asians to 
negati ve life tyle fac tors, explaining the increase 
in ri sk without the need to invoke genetics. 
Culture can and does have a profound 
impact upon how a group views health-related 
lifes tyle choices, uch as frequency of exercise 
or the content of the diet. On the question of 
exercise, a small tudy (n = 56) published by Lip 
and coworkers 16 showed South A ians 
presenting with acute MI were much less likely 
than their Cauca ian counterparts to have 
engaged in regular exerci e. At lea t 12 other 
studie on the general population of South 
A ian in the UK have been done. A systematic 
review revealed that British South Asians were 
generally le physically acti ve than their 
"white" or "Eu ropean" counterparts. 17 
In the fi eld of diet and nutrition, the data 
leave much to be de ired in terms of inter-ethnic 
compari ons. Recent evidence, however, shows 
that Canadi an South Asian on average con ume 
a higher proportion of calo rie as carbohydrate 
than Europeans, Aboriginal , or Chinese 
per ons. 18 In the arne cohort, consumption of 
carbohydrate was inver ely related to serum 
HDL, a potent protecti ve facto r against CAD. In 
preliminary data fro m schoolchildren in the UK 
' South Asian ' tudents consumed les fresh fruit 
and vegetable than white children did .14 South 
Asian cooking, particularl y from northern India 
and Paki tan does not typi cally involve the use 
of raw vegetables, and there i a strong reli ance 
u~on saturated fats for cooking, ev idenced by the 
Widespread use of ghee (clarifi ed butter) and 
khoya or mawa (precipitated whole milk) in 
traditional food. 
The validity of the concept of "Ethnicity" 
The current literature does not recognize 
potential genetic heterogeneity amongst South 
Asians. Whil t thi s overall categorization of 
"South Asian" may be useful "shorthand" that 
might simplify data collection, it is predi sposes 
studies to sampling error: there might be 
substrata in a ample labelled as being "South 
Asian' that have different ri sk than others so 
classified, but which would be falsely seen a 
respresentative of the whole population. 
India, Paki stan , Bangladesh, Nepal, and 
Sri Lanka each have genetically and culturally 
distinct ub-population , and cultural differences 
need not track with genetics. Even in the 
relatively confined space of Sri Lanka, 5 
genetically distinct populations are discernible, 19 
and Tamil and Sinhale e, the two large t 
groups, both have the least in common, from a 
genetic per pective, with India's Veddahs, 
Gujaratis and Punjabis.20 
Whether genetic or cultural, 
heterogeneity can be shown to manifest itself in 
different cardiovascular ri sks between population 
substrata. For in tance, Bangladeshi in the UK 
have been shown to have the highest 
cardiovascular risk of any South Asian group, 
both from biochemical data, and from self-
reported lifestyle factors, with Pakistanis also 
having demonstrably higher risk than Indians.2 1 
These national groupings ("geopraphical 
ancestries") may themselves be futher 
misleading, given the significant cultural and 
genetic overlap between North India and 
Pakistan, as well as the over-representation of 
certain ethnic groups within tho e countries in 
the UK. 
Given the history and ethnology of the 
"South A ian" region, such use of generalized 
ethnic origin as a risk factor cannot be justified 
based upon the current evidence, which is as 
imprecise as studies in "Europeans" that have not 
differentiated between such diverse 
subpopulations as Italians, Finns Icelanders or 
Ashkenazim. 
Conclusions 
Despite the volume of studies published, there is 
no definitive evidence that South Asian origin 
can be yet used as an independent risk factor 
when considering a patient 's CAD risk in order 
to plan interventions. A with most individual 
patient , biochemical and biometric data may be 
useful a "red flags" fo r the physician, and more 
precise indicators o f ri k for the specific patient 
since they more directly reflect potenti al 
underlying disease proce es. C linicians do not 
treat population , they treat indi viduals, and each 
individual' ri sk profile i still related to 
behaviour, regardless of the geneti c contribution. 
Since genetic risk factors are not amenable to 
modification, the sensible course of action is to 
base treatment strategies upon the indi vidual 
patient' hi story and circumstances, and to make 
the same key recommendation to South Asian 
patients as i made to all other patients - the 
adoption of a healthy diet and regular exercise. 
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Feature Article 
A Look at Cardiac Myxoma 
Ahraaz Wyne, Medicine 2010 
Reviewed by Dr. David Masse[ 
Cardiac M yxoma i the most common primary cardi ac tumor. It arises from the endocardium as a lipidic cell mas 
embedded in a va cular myxoid stroma. Mo t myxo mas are sporadic and the cau e is large ly unknown. Fami li a l 
variant with an autosomal domi nant inheritance exist. Myxomas typically develop in female between the eco nd to 
sixth decade of life . C linical manife ta ti on can mimic many cardiac conditions and depend on the natura l behaviour 
of the tumor and its location within the heart, ranging from complete ly a ympLOmatic to causing udden death . 
Establishing an early diagno is is essential and requires imag ing techniques. 2D-Echocardi ography is the diagnostic 
modality o f choice however, ultrafast CT or MRI may be required. The preferred treatment is urgica l re ection which 
is curati ve and should be performed as early a possib le to avo id ystemic complications such a emboli. Patient with 
cardiac myxoma generall y have an excellent prognosis. Following surgical re ecti o n, screening for recurrence is 
prudent, especia ll y amo ng the famili a l variants, where the recurrence rates may be as hi gh a 20%. Myxomas, 
although rare, pre ent a vari ed c linical picture and represent a diagnostic cha llenge. Con eq uentl y, physicians must 
have a high index of su pic ion, since prompt surgical removal improves quality of life and ex tends survival. 
Introduction 
The fir t de cription of a left atrial myxoma is 
accredited to King in 1845. 1 A recent review of 
Carl Rokitansky' collection has revealed a 170-
year old perfectly con erved myxoma of the 
pulmonary valve; the patient died in 1833? 
Prior to 1951 the diagnosis was made primarily 
at postmortem examinations; in that year, an 
intracavitary left atrial tumor was diagnosed by 
angiography.3 The first succe sful excision of a 
left atrial myxoma was performed in 1955.4 
Primary tumors of the heart are rare clinical 
entities and studie estimate the incidence as 
being between 0.0017% and 0.19% at autopsy, 
among unselected patients.5 Cardiac myxomas 
are the most common of the primary cardiac 
tumors comprising about 30-50%. 
Approximately 75% are located in the left atrial 
cavity, 23% in the right atrial cavity, and about 
2% in a ventricular cavity.4•6 While extremely 
rare, tumors may be found in multiple cavities.6 
Cardiac myxomas have varied clinical 
presentations which primarily depend on the 
cardiac chamber where they occur and thu 
present a challenge for early diagnosi s. 
Epidemiology and Clinical Practice 
Epidemiology: Myxomas occur in all age group 
but are particularly frequent between the third 
and sixth decades of life. The youngest known 
patient was a stillborn infant, and the oldest a 95-
year-old woman .4 The majority of myxoma are 
sporadic and tend to be single, atrial , and more 
typically in women. 1 Approximately 10% are 
familial , with an autosomal dominant 
inheritance.7 At pre ent, the Carney complex is 
used to describe an autosomal dominant trait that 
include cardiac myxomas, cutaneous myxomas, 
spotty pigmentations on the skin, 
endocrinopathy, and both endoctine and non-
endocrine tumors. 8 These patient are 
considerably younger at the time of diagnosis 
when compared to patient with sporadic 
4 
myxomas. 
Pathology: Histological examination how 
atrial myxomas arising from the endocardium, 
commonl y attached at the border of the fossa 
ovalis in the left atrium.4 The cells ari e from 
multipotential mesenchymal cells and are 
characterized as lipidic cell embedded in a 
vascular myxoid stroma.4 Tumors vary in shape 
from round-oval to polygonal , and often show 
calcification, necrosis and/or hemorrhage (see 
Figure 1).9 The expres ion of interleuk.in-6 (IL-
6) by atrial myxomas has been widely reported 
in the literature and is believed to aid tumor-cell 
proliferation and differentiation.'' In one series 
of 37 cases of myxoma, 74% howed expre sion 
of IL-6.5 The malignant potential of cardiac 
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Figure 1. Histologic section showing polygonal lipidic 
cells embedded in an acid-rnucopoly accharide va cular 
. 4 
rnatnx. 
myxoma remains doubtful, although there have 
been reports of remote myxomatous growth that 
has embolized.18 
Clinical Presentation: While small myxomas 
can be asymptomatic, the majority present with 
one or more of the tri ad of intracardiac 
obstruction, cardioembolism, and/or nonspecific 
constitutional manifes tations; The clinical 
presentation will vary depending upon the 
physical behaviour of the tumor and its location 
within the heart. 
A. Physical Behaviour: Obstructi on of the 
circulation th rough the heart or heart valves 
commonly gives ri se to ymptom of left-
(dyspnea, recurrent pulmonary edema, 
paroxysmal nocturnal dyspnea, orthopnea) or 
right-sided (peripheral edema, asc ite , fati gue, 
hepatomegaly) heart-failure, often mimicking 
mitral or tri cuspid stenosis. The severity of 
symptom will depend upon the ex tent of 
obstruction and can vary with body po ition. If 
the tumor is large, eas ily defonnable and has a 
long stalk, then temporary complete obstruction 
of the mitral or tricuspid valve ori fice can occur, 
res ulting in syncope, di zziness (20% of pati ent. ) 
or sudden death .4 Interference of the tumor with 
heart valve fun ction may produce symptoms of 
valvular in uffi ciency. Thi s occurs due to 
movement of the mass back and forth between 
the atrium and ventricle (" wrecking ball" effect), 
hampering proper valve closure or damaging the 
A V-valve apparatus (e.g. chordal rupture) .4 
In vasion of the myocardium can cause impaired 
contractility, supraventricular arrh ythmi as, heart 
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block or pericardia! effu sion. If the myxoma 
invades adjacent lung tissue, pulmonary 
symptom can manifest, often mimicking 
bronchogenic carcinoma. 
Embolization, which occurs in 30-40% of 
myxomas, is usually systemic4 but may also be 
pulmonary; it will depend on the tumor's 
chamber of origin . It is for this reason th at 
myxoma should always be on the differential for 
pulmonary embolism, pulmonary hypertension, 
and embolic stroke . 
Constitutional or ystemic symptom such as 
fa ti gue, fever, rashes, joint pains and weight loss 
can also be seen. Laboratory abnonnalities are 
usually seen as elevated inflammatory markers 
(erythrocyte sedimentation rate, serum C-reactive 
proteins and globulin levels) as well as anemi a, 
and high serum interleukin-6 levels.4· 11 
Sometime , low grade but long-standing fever 
can be the only ymptom.9 
B. Location: The majority (75%) of atrial 
myxomas arise in the left atrium and up to 23% 
percent in the right atrium. Mo t arise from the 
inter-atri al septum at the border of the fos a 
ovalis, but they can al o originate, in de cending 
order of frequency, fro m the po terior atri al wall, 
the anterior atrial wall , and the atri al 
appendage. ' .4 Tumors can also grow into the 
atri al lumen and cause ymptoms of blood flow 
ob truction or create mitral insufficiency, which 
are symptoms often assoc iated with commoner 
condition uch a mitral valve di ease, heart 
failure and/or econdary pulmonary 
hypertension. If the tumor moves within the 
atrium, depending on the length of its talk and 
ex tent of attachment to the eptum, symptomatic 
alteration can occur with changes in body 
pos ition. Myxomas can also embolize producing 
serious pulmonary and neuro logic equelae. 
Ph~sical Examination: Phy ical s igns are highly 
van able and depend upon the clinical 
pre entation and the ori ginating chamber of the 
myxoma. For example, right atrial myxomas 
may manifest as elevated jugular venou 
pressure or a pro minent a wave. If the myxoma 
leads to val~ular damage ( tenosi /regurgitation), 
then ystohc or dias tolic murmurs may be 
au cultated. A loud S 1 will be heard if there i a 
delay in mitral valve closure due to tumor 
prolapse into the valve ori fice (mimicking mitral 
stenosi ). The intensity of P2 may also be normal 
or increased, depending upon the presence of 
pulmonary hypertension.4 In many ca es, an 
early dia tolic sound called a ' tumor plop ' i 
heard, as the tumor impacts against the 
endocardial wall m left and right sided 
myxoma .8"10 Upon general examination, 
ystemic signs could include fever, cyanosis, 
clubbing, rash , or petechiae. Patients with 
familial or syndromic forms of myxoma may 
also have feature including skin pigmentations 
or endocrine abnormalities such as Cushing's 
Syndrome.8 
Diagnosis 
The goals of diagno is are three-fold: to ascertain 
whether a tumor exists, determine its location, 
and to characterize it. Diagnosis of myxoma 
require a high index of suspicion and, because 
of the non-specific nature of laboratory testing, 
require various imaging studies.'+ 
Echocardiography first successfully showed a 
left atrial myxoma in 1959.4 Today, because of 
its wide availability and simplicity, 2D-
echocardiography is an excellent noninvasive 
tool for initial evaluation. It typically show 
unimpeded images of the atria, septae and 
ventricles making it helpful in detecting tumor 
location (see Figure 2) and morphology (cysts, 
calcifications, necrotic foci, and hemorrhage).4 
Doppler techniques aid in determining degree of 
cardiac obstruction or valvular damage. In many 
situations a tran esophageal echocardiogram 
(TEE) is preferred as it provides superior images 
Figure 2. One-dimensional echocardiogram 
apical view of a biatrial myxoma.4 
showing characteristics of the tumor and location 
in relation to the interatrial eptum. 
Sometimes, newer imaging techniques 
such a cardiac MRI and ultrafast-CT may be 
required ; both provide noninvasive, high 
resolution cross-sectional v1ews of cardiac 
structures. Cardiac MRI is generally preferred 
becau e of its higher resolution (Figure 3) and 
ability to reflect chemical microenvironments 
within a tumor by differential Tl- and T2-
weighting; however tumors must measure at 
4 J? 13 lea t 0.5 em before they are detectable. · -· CT 
scanning is u eful when MRI is unavailab le or 
contraindicated. Finally, contrast angiography 
ha al o been u ed in the diagnosis of myxoma 
however catheterization is more invasive and 
run the risk of embolizing tumor fragments. A 
study by Agostini et al. howed that positron 
emi ion tomography (PET) could also be used 
in the diagnosis of myxoma, 13 however PET 
remains widely unavailable in Canada and may 
not offer reso lutions comparable to MRI or CT. 
Treatment 
The treatment of choice for myxoma is curative 
surgical resection .4 After a review of the 
literature, there appears to be no known medical 
therapy for shrinking or preventing recurrence of 
myxoma and drugs are primarily used to manage 
symptoms, such as heart failure, or when trying 
to differentiate tumor from thrombus (e.g. 
anticoagulants). Furthermore, there are no 
recommended dietary modifications and life tyle 
activities are permitted as tolerated. 
Once a presumptive diagnosis ha been made, 
most surgeon recommend prompt resection to 
avoid embolic complications uch as sudden 
death. 14"15 Thi s include asymptomatic patients 
Figure 3. A cardiac MRI showing left atri a l myxoma in 
the Transverse (left) and saggital (right) plane .4 
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who have had incidental findings of myxoma 
during routine echocardiography. Surgery entails 
performing a median ternotomy and ubsequent 
tumor excision with the use of mild general and 
deep topical hypothermia, cardioplegic cardiac 
arrest, and cardiopulmonary bypass .~ Care is 
taken to avoid intraoperative fragmentation a all 
chambers of the heart are inspected for 
multifocal disea e. If there is associated valvular 
damage, then thi s is corrected with annulopla ty, 
repair or replacement. 16· 17 The results of surgical 
re ection are generally very good with most 
series reporting operative mortality rates under 5 
percent. 14- 17 Major complications of the surgery 
include tumor embolization, supraventricular 
arrhythmias and requirement of permanent 
cardiac pacing due to conduction di turbances.4 
Alternative surgical approaches using 
endoscopic tumor re ection have also been used 
for their co metic advantage and faster recovery. 
Recurrence is low, close to 5% in pati ents with 
sporadic myxomas but can be a high as 20% 
with the familial variant .7 As such , there is a 
need for careful follow-up and biannual 2-D 
echocardiograms would be reasonable. In rare 
ca e of freq uent recurrence , cardiac 
tran plantation has also been performed. 17 
Conclusion 
Although rare, myxoma IS the mo t common 
type of primary cardiac tumor and requires a 
high index of uspicion. For the patient' illness 
experience, myxoma ranges from being 
completely asymptomat ic to causing severe 
morbidity and sudden death , with symptoms 
suggestive of many card iac causes. Surgical 
removal offers curative treatment with excellent 
prognosis and recurrences are rare. Thi s paper 
has briefly provided an overv iew of cardiac 
myxomas as probably pre enting the most varied 
clinical picture of all cardiac tumors. 
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